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ABSTRACT 
Lung diseases include some of the most widespread and deadly conditions known to affect people around 
the world. The challenges of clinically tackling lung diseases arise from multiple factors associated with 
both diagnosis and treatment strategies. In my thesis work, I addressed the challenges of diagnosis and 
treatment by leveraging tools in computational systems biology that try to account for the effects of the 
multitude of molecular components and their interactions that comprise both the human host and 
microbial pathogens.  
The biomarker discovery field is replete with molecular signatures that have not translated into the clinic 
despite ostensibly promising performance in predicting disease phenotypes. One widely cited reason is 
lack of classification consistency, largely due to failure to maintain performance from study to study.  
This failure is widely attributed to variability in data collected for the same phenotype among disparate 
studies, due to technical factors unrelated to phenotypes (e.g., laboratory settings resulting in "batch-
effects") and non-phenotype-associated biological variation in the underlying populations. These sources 
of variability persist in new data collection technologies.  In the first part of my thesis work, I quantified 
the impact of these combined "study-effects" on lung disease signatures’ predictive performance by 
comparing two types of validation methods: ordinary randomized cross-validation (RCV), which extracts 
random subsets of samples for testing, and inter-study validation (ISV), which excludes an entire study 
for testing. Whereas RCV hardwires an assumption of training and testing on identically distributed data, 
this key property is lost in ISV, yielding systematic decreases in performance estimates relative to RCV. 
Measuring the RCV-ISV difference as a function of number of studies quantifies influence of study-
effects on performance. As a case study, I gathered publicly available gene expression data from 1,470 
microarray samples of 6 lung phenotypes from 26 independent experimental studies and 769 RNA-seq 
samples of 2 lung phenotypes from 4 independent studies.  I found that the RCV-ISV performance 
discrepancy is greater in phenotypes with few studies, and that the ISV performance converges toward 
RCV performance as data from additional studies are incorporated into classification. In this work, I 
showed that by examining how fast ISV performance approaches RCV as the number of studies is 
increased, one can estimate when "sufficient" diversity has been achieved for learning a molecular 
signature likely to translate without significant loss of accuracy to new clinical settings. 
In the second part of my thesis, I turned my focus to an important lung pathogen to engage the challenge, 
ultimately, of therapeutic development. I focused on tuberculosis and its causative pathogen, 
Mycobacterium tuberculosis (MTB), which causes over a million deaths worldwide each year and has 
strains resistant to antibiotics. My goal was to better understand the underlying mechanisms associated 
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with MTB response under different genetic and environmental perturbations of metabolism and 
regulation, which may translate into novel drug targets. As a step toward this goal, I expanded a genome-
scale regulatory-metabolic model for MTB using the Probabilistic Regulation of Metabolism (PROM) 
framework. Our model represents a substantial knowledge base update, incorporating a ChIP-seq based 
transcription factor binding network containing 2556 interactions linking 104 transcription factors (TFs) 
to 647 metabolic genes, as well as an expanded metabolic model that can predict growth in a broad range 
of environmental conditions. My expanded model improves agreement between predicted growth effects 
of TF knockouts and gene essentiality experiments compared to the original PROM MTB model and can 
successfully predict growth defects associated with TF overexpression. The simulated growth predictions 
identify perturbations that lead to condition-specific growth defects, generating experimentally testable 
hypotheses of mechanisms underlying perturbation-induced phenotypes in MTB. 
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CHAPTER 1: Introduction 
Lung diseases pose a major health challenge 
Lung diseases include some of the most widespread and deadly conditions known to affect people around 
the world, causing over four million deaths each year [1]. In the US alone, asthma affects approximately 
30 million people and is the most common chronic disease in children [2]. Chronic obstructive pulmonary 
disease (COPD), a progressive disease which causes difficulty breathing, affects about 16 million people 
and is the fourth leading cause of death worldwide [3]. Lung cancer is the most fatal cancer, leading to 
over 150,000 deaths per year [4, 5]. The infectious disease tuberculosis poses a substantial global public 
health burden, causing approximately 9 million new patients to display active symptoms and 1.4 million 
fatalities every year [6]. Approximately 30% of the world’s population is estimated be infected with the 
causative pathogen, Mycobacterium tuberculosis (MTB) [7]. The challenges of clinically tackling lung 
diseases arise from multiple factors associated with both diagnosis and treatment. 
Standard clinical diagnosis approaches for many lung diseases currently emphasize patient history, 
symptoms, and imaging outcomes. The subjective interpretation of these macroscopic evaluations does 
not always accurately reflect the biochemical processes instigating most pulmonary diseases, leading to 
delayed diagnosis that can significantly reduce quality of life and increase associated mortality rates for 
patients [5, 8]. In the case of asthma and COPD, late detection leads to significantly reduced quality of 
life because the effects of the disease are not fully reversible. Most urgently, in the case of lung cancer, 
the tumor has often metastasized beyond the chest wall by the time of diagnosis. This late-stage diagnosis 
undermines the efficacy traditional treatments. Two-thirds of lung cancer patients are diagnosed at a late, 
metastatic, stage, which has a five-year survival rate of 2%, whereas 49% of patients diagnosed at the 
earliest stage can survive five or more years [5]. Improved approaches to diagnosis would facilitate better 
outcomes for treatment efficacy over a broad spectrum of lung diseases. 
In the case of tuberculosis, treatment strategies are also particularly in need of improvement. The current 
standard treatment for drug-susceptible tuberculosis involves treating with first-line drugs, which inhibit 
MTB proteins responsible for metabolism and transcription, dosed in combination for approximately 6 
months [9]. The long duration of the drug regime makes it time and resource intensive to treat patients 
and, along with drug toxicity, reduces patient compliance, which contributes to the emergence of drug-
resistant MTB strains [10]. Despite the increasing incidence of multi-drug resistant and extensively-drug 
resistant strains of MTB, current mainstay therapies recommended by the World Health Organization are 
  2
based on drugs that were developed prior to the 1980s [10]. Therefore, there is a strong need to develop 
new approaches for treating MTB [11]. 
In my thesis work, I addressed the challenges of diagnosis and treatment by leveraging tools in 
computational systems biology. These systems biology approaches try to account for the effects of the 
multitude of molecular components and their interactions that comprise both the human host and 
microbial pathogens. To tackle the disease diagnosis problem, I examined statistically-driven models that 
infer patterns from high-throughput datasets of the molecular state of the affected host tissue in a set of 
different lung diseases. I investigated the challenge of learning diagnostic molecular signatures that stems 
from site-specific variability in data measurements, and I found some approaches to mitigate this issue 
and achieve more robust disease diagnosis outcomes. In engaging the challenge of therapeutic 
development, I focused on MTB, the causative pathogen of the lung disease tuberculosis. I refined the 
genome-scale mechanistic models of metabolism and regulation for the MTB and integrated these models 
to simulate the effects of transcription factor and metabolic gene perturbations on growth under different 
environmental conditions, probing for putative vulnerabilities that can be further explored in follow-up 
experiments. 
Monitoring host transcriptomes to find robust molecular disease diagnostics  
A potentially valuable source of information to facilitate more effective diagnosis comes from molecular 
markers in bodily fluids, as these are comparatively non-invasive to sample and facilitate longitudinal 
monitoring of disease state. Many studies in search of molecular diagnostics have been conducted on the 
genome scale, focusing on the expression levels of all human genes. Despite the latent wealth of 
information found from bodily fluids, discovering viable biomarkers for disease has so far yielded limited 
few that survive through clinical trials; most markers have substantial false positive rates [12-14].  
A major challenge facing molecular disease classification efforts is that of reproducibility. This is at least 
partially due to the fact that measurements of dynamically changing biomolecules can be affected by a 
broad host of causes and are therefore highly heterogeneous. For example, mRNA levels, which can be 
measured comprehensively with microarrays and RNA-seq, are highly sensitive to heterogeneity in 
intrinsic biological factors that can be completely unrelated to the phenotype. This biological 
heterogeneity is further confounded by variation in technical factors during sample preparation, data 
collection, and data processing. Typically, disease classification studies collect and process data from a 
limited number of patient samples at a single site, which makes it difficult to sufficiently sample the full 
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extent of variability of the entire population, and therefore makes it difficult to learn classifiers that are 
representative of the phenotype as a whole. 
In my work described in Chapter 2, I quantified the impact of measurement variability in microarray and 
RNA-seq gene expression measurements on disease classification performance. I found that the 
variability in expression measurements across datasets collected from one or two experimental studies can 
drastically reduce classification performance when validating on data from an independent study. 
However, by integrating the data from a greater number of studies, one can provide a more complete 
representation of the heterogeneity of a phenotype, resulting in improved independent validation 
classification performance. 
Mechanistic modeling of a pathogen to predict candidate drug targets 
A promising approach to aiding the search for novel drug targets has been to construct and study models 
that recapitulate the underlying mechanisms leading to growth and other phenotypes in biological 
systems. For example, genome-scale mechanistic models of metabolism have been used to simulate 
growth and metabolic phenotypes under gene deletion conditions in multiple microbial pathogen systems 
to search for candidate metabolic gene drug targets [15]. Using mechanistic models to simulate growth 
phenotypes under different genetic and environmental perturbations can aid the understanding of the 
mechanisms of action for existing drugs and suggest potential alternative targets that share the same 
mechanisms. Moreover, using genome-scale models of metabolism to systematically screen in silico the 
effect of all genetic perturbations for potential target genes of interest can aid therapeutic development 
efforts by filtering and prioritizing the most promising genes for subsequent in-depth experimental 
characterization and application. 
Constructing models that represent the underlying mechanisms of biological systems is a data-heavy 
endeavor that is limited by our incomplete knowledge of and ability to represent the systems we are 
modeling. For example, genome-scale models of metabolism are limited by large gaps in our knowledge 
of the complete set of biochemical reactions that occur in different organisms, and by our incomplete 
knowledge of which genes are responsible for carrying out these metabolic functions. Construction of 
genome-scale metabolic models is further hampered by the difficulties consolidating information from a 
broad range of sources located in a host of databases and different literature articles. Reconciling 
ambiguities and inconsistencies in the nomenclature of reactions and metabolites among the different 
sources of biochemical information necessitates an extensive manual curation process for high quality 
genome-scale metabolic models, rendering comprehensiveness a difficult goal to achieve for a single 
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reconstruction. When multiple efforts are undertaken to generate genome-scale metabolic models of a 
particular system, there is often non-overlapping knowledge contained within these models, with different 
subsets of reactions and genes represented in the different versions. Thus, comparing and consolidating 
information from different genome-scale metabolic models of metabolism can help to expand and 
improve the scope of model updates. 
My work described in Chapter 3 focused on generating an updated genome-scale metabolic model of 
MTB based on reconciliation of metabolic information contained in five different existing genome-scale 
metabolic network representations. The goal for this model update was to maximize the number of 
reactions with literature evidence of existence within MTB, so I focused on integrating non-overlapping 
reactions with literature evidence from the different metabolic models. I validated the updated model 
based on its ability to predict growth phenotypes under different media conditions and under different 
single gene deletion perturbations. The resulting updated model can predict growth phenotypes under a 
broader scope of media conditions than the previously existing metabolic models.   
Another important type of biological network for which mechanistic models have been constructed is 
gene regulation. Transcriptional regulatory networks play a key role in tuning organism responses to 
adapt to condition-specific perturbations, which makes their study particularly relevant for MTB, an 
organism that can survive under a broad range of stresses. Genome-scale mechanistic models of 
regulation have faced challenges on two different fronts. Efforts at reconstructing the regulatory network 
remain limited in scope because experimental characterizations of regulatory interactions have until very 
recently been limited to low-throughput efforts. Given that there are many more regulatory interactions 
than metabolic reactions, that metabolic reactions are more conserved across species than regulatory 
interactions (which enables extrapolating aspects of metabolic knowledge from well-studied organisms), 
and that metabolic reactions have been studied for a longer time than regulatory interactions, models of 
regulation based on literature evidence alone will be limited comprehensiveness. Alternatively, 
substantial effort has been directed towards attempting to statistically infer transcriptional regulatory 
networks from gene expression data [16]. Although significant signal in predicting interactions can be 
extracted from inference-based methods for bacterial regulatory networks, overall predictive performance 
remains low (area under a precision-recall curve yields less than 15% for all methods tested by Marbach 
et al.) because of the complexity and diversity of the underlying regulatory interactions [16]. Recent 
advances have facilitated high-throughput characterization of transcription factor-DNA binding on a 
genome-scale for many transcription factors (TFs) via performing ChIP-seq with tagged TFs [17]. Taking 
advantage of such comprehensive TF binding information in concert with gene expression information, I 
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have constructed a more comprehensive experimentally-based identification of regulatory interactions for 
MTB [18].  
The phenotypic consequences of transcriptional regulatory network perturbations have been studied in 
two main ways. The primary approach has been to study the effect of different perturbations, such as 
changes in the expression of different transcription factors, on the other genes in the regulatory network. 
Studying time-course gene expression consequences can shed light on regulatory dynamics and identify 
gene expression steady states and transition states [19-22]. Alternatively, more extended phenotypic 
consequences of regulatory perturbations, such as the growth consequences of TF perturbations, can be 
analyzed by integrating the regulatory network with the metabolic network [23-26]. Many challenges 
remain in regulatory-metabolic network integration. Most regulatory-metabolic models include Boolean 
regulatory rules that were manually formulated, rendering such a model building process difficult to apply 
to large-scale regulatory networks. In contrast, the Probabilistic Regulation of Metabolism (PROM) 
framework [23] learns the strength of influences between TFs and metabolic target genes from gene 
expression data, but the original PROM model for MTB was limited by the incomplete representations of 
the regulatory and metabolic networks provided by the respective model components and by yielding 
predictions the metabolic consequences of only TF deletions in one environmental condition.  
In Chapter 4, I describe the generation of an updated PROM regulatory-metabolic model for MTB using 
the updated genome-scale metabolic model discussed in Chapter 3 and a regulatory network that I helped 
to generate based on ChIP-seq experiments [18]. I used this updated regulatory-metabolic model to 
simulate the growth phenotypes of TF knockouts and overexpression for a broad range of environmental 
conditions. The simulations identified multiple perturbations that were predicted to yield condition-
specific MTB growth defects and are promising targets for follow-up experimental characterization. 
Collectively, my work shows that applying statistical and mechanistic modeling techniques to studying 
both the human host and the microbial causative agent can improve our understanding of disease 
phenotypes and help to refine strategies for development of diagnostics and therapeutics. 
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CHAPTER 2: Measuring the Effect of Inter-study Variability on 
Estimating Prediction Error1 
ABSTRACT 
Background: The biomarker discovery field is replete with molecular signatures that have not translated 
into the clinic despite ostensibly promising performance in predicting disease phenotypes.  One widely 
cited reason is lack of classification consistency, largely due to failure to maintain performance from 
study to study.  This failure is widely attributed to variability in data collected for the same phenotype 
among disparate studies, due to technical factors unrelated to phenotypes (e.g., laboratory settings 
resulting in "batch-effects") and non-phenotype-associated biological variation in the underlying 
populations.  These sources of variability persist in new data collection technologies.  Methods: Here we 
quantify the impact of these combined "study-effects" on a disease signature’s predictive performance by 
comparing two types of validation methods: ordinary randomized cross-validation (RCV), which extracts 
random subsets of samples for testing, and inter-study validation (ISV), which excludes an entire study 
for testing.  Whereas RCV hardwires an assumption of training and testing on identically distributed data, 
this key property is lost in ISV, yielding systematic decreases in performance estimates relative to RCV.  
Measuring the RCV-ISV difference as a function of number of studies quantifies influence of study-
effects on performance.  Results: As a case study, we gathered publicly available gene expression data 
from 1,470 microarray samples of 6 lung phenotypes from 26 independent experimental studies and 769 
RNA-seq samples of 2 lung phenotypes from 4 independent studies.  We find that the RCV-ISV 
performance discrepancy is greater in phenotypes with few studies, and that the ISV performance 
converges toward RCV performance as data from additional studies are incorporated into classification.  
Conclusions: We show that by examining how fast ISV performance approaches RCV as the number of 
studies is increased, one can estimate when "sufficient" diversity has been achieved for learning a 
molecular signature likely to translate without significant loss of accuracy to new clinical settings. 
INTRODUCTION 
There has been substantial effort to develop disease diagnostic strategies based on analyzing large-scale 
molecular information (i.e., omics data) from patients. Numerous studies aiming at developing such 
                                                            
1 This chapter is the reprint of a published article. The citation is as follows: Ma S, Sung J, Magis AT, 
Wang Y, Geman D, and Price ND. “Measuring the effect of inter-study variability on estimating 
prediction error.” PLoS ONE (2014) 9(10): e110840. doi:10.1371/journal.pone.0110840. 
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molecular diagnostics have examined omics data, both directly [5, 27-30] and through meta-analyses [31-
33]. Although many reports have shown high performance estimates for predictive disease classification, 
identifying molecular signatures that give consistent results across multiple trials remains a challenge [34-
36]. This discrepancy between high reported performance estimates and the relative paucity of robust 
omics-based tests delivered to the clinic was the subject of a recent in-depth study by the United States 
Institute of Medicine [37]. While the general issues discussed exist across all omics data platforms, herein 
we will focus on large repositories of transcriptomics data because of broad availability from many 
studies, especially those conducted on Affymetrix microarrays (the most abundant source), as well as 
recent RNA sequencing (RNA-seq) data. 
A major factor hindering the consistency of identified disease classifiers and their performances stems 
from variability in omics data attributed to technical and biological influences that are unrelated to the 
specific phenotypic differences under study. Gathering gene expression data from different batches—
processed at a specific experimental site and time—introduces technical variability, termed “batch-
effects” [38]. Moreover, diversity among studies is present and often significant even in the absence of 
batch-effects because of intrinsic biological variation, including geographic differences in patient 
subpopulations due to disease heterogeneity [39-43]. Both batch-effects and intrinsic biological variation 
introduce site-specific variability that can bias the selection of classifiers by obscuring the phenotype-
specific molecular signal.  
We use the term study-effects herein to describe the joint variability that stems from both technical 
variation introduced by batch-effects and the biological variation associated with population 
heterogeneity. Importantly, the presence of these study-effects is not necessarily a reflection of the quality 
of the laboratories or experimental studies; rather, they emphasize that measured gene expression is 
sensitive to a broad range of influences. Although numerous excellent studies have examined [44-46] and 
attempted to mitigate [47-56] site-specific variability from technical batch-effects, which have been 
summarized and compared elsewhere [47, 57-59], no definitive solution for study-effects has been 
adopted by the molecular diagnostic community at large.  
The motivation of our study was to examine the influence of study-specific variability in gene expression 
data on disease classification prediction error and suggest how to mitigate this influence to achieve 
improved classification performance. Our approach to measuring the influence of study-effects on 
classification involved assessing classification performance with a study-centric validation strategy. In 
inter-study validation (ISV), we identified phenotype-specific classifiers based on data pooled from all 
studies except for one, and then evaluate the predictive performance on the excluded study. This process 
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was repeated for all studies, leaving each one out for testing and training a predictor on the data combined 
from all others. This differed from randomized cross-validation (RCV), the standard in machine learning, 
wherein a random subset of the pooled data, for example ten percent in ten-fold RCV, was set aside for 
testing, and the predictor is identified from the pooled data excluding this subset. This process was then 
repeated, for example ten times. The critical difference between these validation strategies was that RCV 
(and other methods that split data randomly) estimated classification error under a condition (namely 
random sampling) in which the training and testing data were drawn from the same distribution. In other 
words, the assumption was made, at least implicitly, that future samples from other studies encountered 
by the classifier would display the same statistical properties as the training data—a condition that is often 
violated in real world settings. Hence, randomized sampling obscures systematic differences in expression 
distributions associated with study-effects. In contrast, ISV was sensitive to study-effects because it 
preserved the variation among studies (i.e. the training and test sets are not necessarily identically 
distributed). Consequently, estimates of classifier performance derived using ISV were often low when 
there were expression patterns that varied substantially between studies within phenotypes. Therefore, the 
magnitude of discrepancies between performance estimates from ISV and RCV reflected the extent of 
study-effects. We refer to the comparison of ISV and RCV performance estimates as comparative cross-
validation analysis (CCVA). CCVA could be applied in subsets of study comparisons in various ways, 
for example as a measure of how well controlled a multi-site clinical trial is performing in terms of cross-
site variation. 
In this study, we used comparative cross-validation analysis to gauge the extent to which study-effects 
confound gene expression-based disease classification performance. We found that including data from 
more studies improved representation of biological heterogeneity during the disease signature learning 
process, which mitigated the influence of study-effects. By tracking the difference between the ISV and 
RCV performance, we measured the extent to which introducing heterogeneity into the training data 
alleviates the influence of study-effects on disease classification and can thereby estimate when sufficient 
data had been incorporated to generate classifiers that are robust to study-specific biases.  
MATERIALS AND METHODS 
Data Preprocessing 
For the microarray data, we downloaded the raw .CEL files of each microarray experiment, either from 
the Gene Expression Omnibus [60], ArrayExpress [61], or from files kindly provided by the original 
authors of the experiments. We developed a custom pipeline in MATLAB to preprocess the .CEL files of 
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the samples across all studies in a consensus set using the GCRMA method [62] (see Appendix A for 
details). We provided this uniformly processed dataset to the community as a resource to download at our 
website (https://price.systemsbiology.net/measuring-effect-inter-study-variability-estimating-prediction-
error), and we added our uniformly preprocessed dataset to GEO with accession number: GSE60486.  It 
should be noted that this dataset is a compilation and standardization of data generated from other groups. 
For the RNA-seq data, we downloaded raw fastq files from the Sequence Read Archive [63] or CGHUB 
and extracted gene expression counts using STAR alignment [64] and HTSeq software (http://www-
huber.embl.de/users/anders/HTSeq/doc/overview.html). We consolidated the data across studies and 
performed correlation analysis using Python. 
Comparative cross-validation analysis (CCVA)  
To estimate the significance of study-effects on classification performance, we compared two metrics for 
evaluating classification sensitivity: inter-study validation (ISV) and the commonly used randomized 
cross-validation (RCV). For each method, classification performance metric we used was the phenotype-
specific sensitivity, defined as the fraction of samples of that phenotype that were correctly identified by 
the learned molecular signature. 
In ISV, the expression data from each experimental study was excluded from the training set used to find 
diagnostic classifiers. Data from the remaining studies was used to train a classifier using an algorithm of 
choice. The data from the excluded study acted as a test set to evaluate the performance of a classification 
algorithm. This ISV was repeated for every study included in the analysis, and the sensitivity for each 
phenotype evaluated on each excluded study was reported. To mitigate sample number bias in training, 
we implemented a stratified training loop (see Appendix A for details).  
We implemented ten-fold RCV, in which one-tenth of the samples combined from all studies for each 
phenotype was randomly excluded from the training set in each iteration of validation. Classifier training 
was executed on the remaining nine-tenths of the data, and the excluded tenth of the data was used to 
evaluate predictive sensitivity. The process was iterated ten times so that each excluded test set was 
disjoint. The average sensitivity across all ten iterations for each phenotype was reported. 
For each phenotype, we compared the average of the ISV sensitivities across all studies of that phenotype 
against the phenotype-specific sensitivity obtained by ten-fold RCV. This approach was implemented in 
MATLAB (see https://price.systemsbiology.net/measuring-effect-inter-study-variability-estimating-
prediction-error for code). 
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Cumulative CCVA 
We also investigated the effect of including different numbers of studies in the considered dataset on ISV 
and RCV outcomes. In this cumulative CCVA, we focused on the three phenotypes with greater than five 
independent studies: ADC, SCC, and NORM. For each of these phenotypes, we combined data from 
}1,...,2{  pNn  studies of the phenotype under consideration ( pN is the total number of studies for the 
phenotype under consideration) along with data from studies that lack the phenotype under consideration.  
We performed ISV and RCV on this study-controlled dataset and reported the ISV and RCV sensitivities 
for the phenotype under consideration. For each n, five random selections of n studies were selected for 
inclusion, and the ISV and RCV results were averaged over these independent iterations. Note that 
applying this analysis to a dataset consisting of pNn   studies of the phenotype under consideration 
would be equivalent to the standard CCVA. This approach was implemented in MATLAB (see 
https://price.systemsbiology.net/measuring-effect-inter-study-variability-estimating-prediction-error for 
code). 
Classification methods applied 
We evaluated predictive performance of support vector machine (SVM) [65] and Identification of 
Structured Signatures And Classifiers (ISSAC) [33]. We choose to use these algorithms because in 
addition to demonstrating significant classification capability, the methods were based upon disparate 
classification strategies. SVM was designed to find an optimal discriminating hyperplane based on a set 
of input feature genes, which we selected using the F-score feature selection metric [66] (see Appendix A 
for details). In contrast, ISSAC was designed to select an optimized set of feature pairs as a multi-
phenotype classifier, wherein classification was based on comparing expression values within each pair. 
We performed feature selection based on the training data within each iteration of validation. We useed 
existing MATLAB implementations of these algorithms [33, 67]. 
Statistical significance testing 
Non-parametric significance tests were used where possible, with p < 0.05 set as the significance 
threshold. 
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RESULTS 
Overview of microarray data assembled 
We assembled lung-related expression data from two publicly available online databases: Gene 
Expression Omnibus [60] and ArrayExpress [61]. Our analysis focused on the lung because lung diseases 
pose significant health challenges that would benefit from improved diagnostic methods [2, 5, 8, 68, 69] 
and because there exists a wealth of gene expression datasets generated repeatedly for multiple lung 
diseases. We examined data from non-diseased tissue (NORM) and from five common lung disease 
phenotypes: three types of non-small-cell lung cancers (adenocarcinoma (ADC), squamous cell 
carcinoma (SCC), and large cell lung carcinoma (LCLC)) as well as two non-cancer diseases (asthma 
(AST) and chronic obstructive pulmonary disease (COPD)). These studies were performed by 
laboratories that sampled geographically distinct patient populations; used different protocols for tissue 
sample collection and preparation; measured gene expression using different Affymetrix microarray 
platforms; and utilized different data preprocessing methods to yield gene expression values from 
hybridization intensities measured by the microarrays. We restricted ourselves to microarray platforms 
developed by Affymetrix to eliminate additional sources of variability associated with microarray 
technology, which have been covered elsewhere in the literature [40]. Our assembled gene expression 
dataset consisted of 1,470 samples collected by 26 independent experimental studies. A summary of the 
data included in our analysis is shown in Table 1 (see Table 11 for a complete list of experimental study 
sources; some studies measured more than one phenotype considered in our analysis). Microarray sample 
sizes within each phenotype ranged from 49 to 580. In each case, we preprocessed the raw data using our 
custom pipeline to create a consistent dataset with minimal algorithmic sources of variance (see Appendix 
A for rationale and details). We used this uniformly preprocessed dataset for all subsequent classification 
analyses described in this study. 
Comparative cross-validation analysis evaluates influence of study-effects on classification 
performance 
We applied CCVA on our lung microarray dataset using two very different multi-class classification 
schemes—the commonly used linear one-versus-one multiclass support vector machines (SVM) [65] and 
Identification of Structured Signatures And Classifiers (ISSAC) [33] (see Appendix A for descriptions of 
these algorithms)—to demonstrate that the results throughout were largely independent of the 
classification method selected. Figure 1 shows the estimated ISV sensitivities for each study, grouped by 
phenotype, calculated by ISSAC and SVM. The figure also shows the average ISV sensitivities across all 
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studies of each phenotype (dashed lines), as well as the sensitivities obtained by ten-fold RCV for each 
phenotype (solid lines). The qualitative outcomes of ISV were consistent across the two classification 
schemes. The consistency of the results provided evidence that results herein were largely independent of 
the specific classification method used. There was no significant correlation between ISV or RCV 
performance with sample size of study and no significant correlation between ISV performance and RCV 
performance (p > 0.05, see Appendix A for details and for plot of ISV performance as function of study 
sample sizes). 
Number of independent studies affects the influence of study-effects on performance 
The results in Figure 1 showed that phenotypes with data from larger numbers of studies have smaller 
differences in RCV and ISV performance because their ISV sensitivities were greater than those in 
phenotypes with fewer studies. We observed a significant negative correlation between the difference of 
ISV and RCV sensitivity across all studies for a phenotype and the number of studies belonging to that 
phenotype (Spearman’s rho = -0.93, p < 0.05 for SVM and ISSAC). ISV sensitivities of SCC, ADC, and 
NORM—phenotypes with data from seven or more independent studies—differed from RCV sensitivities 
only by 0.07, 0.01, and 0.04, respectively for SVM, and by 0.03, 0.03, and 0.02 for ISSAC. In contrast, 
phenotypes with data from few studies independent studies (AST, 3 studies; LCLC, 4 studies; COPD, 4 
studies) had low ISV sensitivities even when the corresponding sensitivities from RCV were high, 
resulting in greater gaps between RCV and ISV performance (RCV - ISV of AST = 0.76, LCLC = 0.13, 
and COPD = 0.32 for SVM; RCV- ISV of AST = 0.69, LCLC = 0.20, and COPD = 0.35 for ISSAC).  
Besides yielding improved ISV performance relative to RCV, phenotypes with more studies achieved 
more consistent ISV results. We quantified ISV consistency by the coefficient of variation (CoVar), 
which is equal to the standard deviation of ISV sensitivities across studies belonging to a particular 
phenotype divided by the average. Lower CoVar values translate to higher consistency. Phenotypes with 
fewer studies, such as AST and COPD, had low consistency (CoVarAST = 1.7, CoVarCOPD = 1.1 for SVM; 
CoVarAST = 0.54, CoVarCOPD = 1.0 for ISSAC), whereas SCC and ADC had higher consistency (CoVarSCC 
= 0.30, CoVarADC = 0.17 for SVM; CoVarSCC = 0.12, CoVarADC = 0.11 for ISSAC).  
To measure the extent to which the number of studies affected CCVA performance, we calculated ISV 
and RCV while varying the number of studies included in each phenotype. Figure 2 shows the phenotype-
averaged ISV and RCV sensitivities for ADC, SCC, and NORM, as the number of studies considered in 
CCVA was varied based on SVM and ISSAC (see Appendix A for plot of ISV sensitivities as a function 
of the training set sample sizes). Each point in the figure represents the average and standard deviation of 
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ISV and RCV estimates calculated from five independent sampling combinations of input training studies 
(see Cumulative CCVA section in Methods for details). 
When only two studies were considered in analysis, average ISV sensitivity for each phenotype was 
substantially lower than the corresponding RCV sensitivity, showing that results learned from one study 
context did not translate well to a second. Each phenotype achieved higher sensitivity when data from a 
greater number of studies were used for signature learning (Spearman’s rho = 0.65 for SVM, rho= 0.57 
for ISSAC; p < 0.05 for both methods correlating mean ISV sensitivity with the number of phenotype-
specific studies included over all three phenotypes). Moreover, we observed a converging of ISV 
sensitivity toward the corresponding RCV sensitivity as additional studies were added, although the rates 
of convergence differed between phenotypes. As the ISV sensitivity approached RCV sensitivity, the 
incremental improvement of average ISV sensitivity dropped with the addition of further studies. We also 
observed a significant negative correlation between the CoVar and the corresponding ISV sensitivity 
(Spearman’s rho = -0.64 for SVM, rho = -0.78 for ISSAC; p < 0.05 for both methods correlating over all 
three phenotypes), indicating enhanced signature performance and consistency with the addition of data 
from different studies. Further analysis showed that the trends of ISV performance were reflected in 
large-scale differences in the expression profiles that can be visualized by principal component analysis, 
and that these performance trends also had association with consistency of selected gene signatures (see 
Appendix A). These results demonstrated that integrating gene expression data across diverse studies 
could strengthen phenotype-associated signal that translated into new study contexts. 
Study-effects similarly impact classification performance in RNA-seq data 
Advances in sequencing technologies have recently enabled large-scale RNA-seq studies to measure gene 
expression for disease classification [70]. Although RNA-seq offers many advantages over microarrays 
[70, 71], study-specific variability has also been observed in RNA-seq data [45, 46]. To evaluate the 
extent that the CCVA results from microarray data also apply to RNA-seq, we examined RNA-seq data 
collected from four independent studies consisting of ADC and NORM data: GSE37764 (11 ADC, 12 
NORM samples) [72], ERP001058 (90 ADC samples and 76 NORM samples) [73], TCGA (448 ADC 
samples) [1], and dbGaP (132 NORM samples) [74]. Correlation and classification analysis based on 
study label on data from GSE37764 and ERP001058 confirmed that study-effects are also influencing 
these RNA-seq datasets (see Appendix A).  
The CCVA results on data from these four studies indicated two key results. First, the gap between RCV 
and ISV performance was smaller for ADC when the RNA-seq studies are analyzed (RCV-ISV difference 
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of 0.10, Figure 3A) than when the same number of ADC microarray studies was analyzed (difference of 
0.26). This suggested that ADC classification based on RNA-seq data from three independent studies was 
not significantly impacted by study-effects (an improvement over ADC classification based on the same 
number of microarray studies). To substantiate this result, we further estimated classification performance 
when only one study was used to train a classifier (Figure 3B). The bars represent classification 
sensitivities achieved on the studies excluded from training, whereas the square points represent RCV 
sensitivities on the training studies. ADC sensitivity on studies excluded from training (0.94±0.05) 
remained high and close to the RCV sensitivity (0.96±0.04) even when only one study was used to train.  
Second, we found that, as with microarray data, increasing RNA-seq dataset diversity by including 
additional studies into the analysis also mitigated the impact of study-effects on classification outcomes. 
For example, ISV sensitivity calculated from NORM RNA-seq data (0.68±0.21) was significantly lower 
than corresponding RCV sensitivity (0.98±0.03) (p < 0.05, Wilcoxon ranksum test), indicating that 
NORM sensitivity was indeed compromised by study-effects. Notably, we found that NORM ISV 
sensitivity, which was achieved by learning a molecular signature from two NORM training studies 
(0.68±0.21), was greater than the sensitivity achieved when only one NORM study was used to learn a 
molecular signature (0.56±0.26). Increasing the number of RNA-seq studies included in training 
improved NORM classification performance on untrained studies and did not significantly change ADC 
performance on untrained studies, suggesting that greater benefit in classification could be gained by the 
integration of data from additional NORM RNA-seq studies.  
DISCUSSION  
Generating molecular signatures that yield consistently high predictive capability in diagnostic tests 
remains a critical challenge in omics-based biomarker discovery. We found that study-effects stemming 
from both technical and biological variability substantially decreased predictive performance and 
consistency when data from only a few studies were considered in learning molecular signatures. 
However, our results showed that incorporating data from additional independent studies mitigated the 
impact of study-effects, thereby reducing the predictive error. The qualitative trends of our study-effects 
results remained consistent across microarray and RNA-seq datasets. Given that study-effects also 
account for intrinsic biological heterogeneity, the trends associated with study-effects are relevant to 
classification even with improved technologies. 
A significant source of variability arises not from technical batch-effects but rather is an inevitable 
consequence of the inherent heterogeneity of many disease phenotypes. Given that study-effects 
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associated with disease heterogeneity are biological, they can best be accommodated by collecting data 
from multiple sources. The key point is that the diversity represented in the training and test set needs to 
reflect the range of diversity expected in the clinical setting. Subpopulations from different studies have 
different underlying distributions of expression, so sampling data from multiple independent studies 
improves the approximation of the global distribution across multiple sites – even when sample sizes are 
held constant -- which aids the identification of consistent classifiers. Therefore, the improvement in 
classification performance that results from training classifiers on larger numbers of studies highlights the 
need to incorporate more population heterogeneity in future biomarker discovery studies by integrating 
data from multiple sites, including additional sites in test validation.  
Comparative cross-validation analysis provides a quantitative basis for prioritizing strategies for 
improving classification of different phenotypes. For example, our CCVA results highlight phenotypes 
for which diagnostic reproducibility was most greatly affected by study-effects. These phenotypes are the 
most suitable candidates for further data gathering and analysis to immediately yield better classification 
outcomes. In contrast, in phenotypes with average ISV sensitivities that approach RCV sensitivities, our 
results suggest that, because of the difficulty of the gene expression-based classification problem, simply 
gathering more gene expression data and using the same algorithms would not likely substantially 
improve performance. In these cases, leveraging other strategies for classification, including redefinitions 
of molecular phenotypes, integration of multi-omic data, and contextualization with biological networks, 
may be more beneficial to finding classifiers with more consistent performance. By measuring the 
improvement in classification once study-effects have been mitigated, CCVA can be used to guide future 
data gathering efforts. 
CONCLUSIONS 
In this study, we quantified the degree of impact of technical and biological "study-effects" on disease 
classification performance. We found that learning diagnostic signatures on larger numbers of studies 
compensated for study-effects and resulted in marked improvements in classification performance. 
Moreover, we could estimate when "sufficient" diversity had been achieved for learning classifiers that 
were likely to translate effectively to new clinical settings. These results are relevant to phenotype 
prediction using data across measurement technologies. Our finding that study-effects can be quantifiably 
mitigated by introducing data collected from additional studies has applicability to disease classification 
study design strategies. It has clear implications for study design because diversity of samples in the 
training set (e.g. from multiple sites) shows markedly better consistency in predictive accuracy when 
taken to new clinical sites, as is a needed step on the path to clinical use. This underscores the need to 
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incorporate more population heterogeneity in future classification studies by integrating data from 
multiple sources. Additionally, we find that different phenotypes require different degrees of training 
heterogeneity to mitigate study-effects. Applying comparative cross-validation analysis, we can 
discriminate between phenotypes that would benefit from for further data gathering to increase training 
heterogeneity from the phenotypes may require different analysis strategies to reduce predictive error. 
Therefore, our approach provides a computational tool for prioritizing strategies to improve disease 
classification. 
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FIGURES AND TABLES 
 
Figure 1. Inter-study validation and randomized cross-validation performance. The graphs show ISV and RCV 
results from SVM (A) and ISSAC (B). For clarity, the Study ID labels have been excluded from this visualization 
(see Appendix A for expanded versions of these plots that include the individual Study ID labels). The colored bars 
report sensitivities achieved on the validation study designated in the horizontal axis (e.g., the bar on the farthest left 
in (A) shows that 74% of ADC samples in the first ADC study are correctly classified by SVM when that study is 
excluded from training). The order of studies in the horizontal axis is identical for panels (A) and (B). Dashed lines 
represent average ISV sensitivities for each phenotype. Solid lines report corresponding ten-fold RCV sensitivities 
of each phenotype. 
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Figure 2. Inter-study-validation and randomized cross-validation results as function of number of studies 
included in analysis. Average ISV (black circles) and RCV (white squares) sensitivities as a function of the number 
of studies included, for ADC (A, D), SCC (B, E), and NORM (C, F), using SVM and ISSAC classifiers.  
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Figure 3. Inter-study validation performance in RNA-seq data based on SVM. (A) The colored bars report ISV 
sensitivities achieved by validating performance on the study designated in the horizontal axis. Dashed lines 
represent average ISV sensitivities for each phenotype. Solid lines report corresponding ten-fold RCV sensitivities 
of each phenotype. (B) The colored bars report average sensitivities from validating on studies excluded from 
training. Squares represent corresponding RCV sensitivities from the studies included in the training set. Results 
were averaged across the different combinations of training studies, and the error bars report the standard deviation 
of the results.  
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Table 1. Summary of lung disease microarray data. The number of samples (n=1470), number of studies (n=26), 
types of platforms, and the methods of tissue extraction used to collect samples in the studies are shown. The 
platform labels represent: 1) Affymetrix Human Genome U133 Plus 2, and 2) Affymetrix Human Genome U133A. 
The sampling method labels represent: A) surgical resection, B) bronchoscopy brushing, C) bronchoalveolar lavage. 
See Table S2 for detailed information on the studies. 
Disease Label Platforms # Studies # Samples Sampling Method 
Adenocarcinoma ADC 1,2 14 580 A 
Squamous Cell Carcinoma SCC 1,2 7 239 A 
Large Cell Lung Carcinoma LCLC 1,2 4 49 A 
Asthma AST 1 3 70 B,C 
Chronic Obstructive 
Pulmonary Disease 
COPD 1,2 4 63 A,B 
Normal NORM 1,2 17 469 A,B 
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CHAPTER 3: Metabolic Modeling of Mycobacterium tuberculosis2 
ABSTRACT 
Mycobacterium tuberculosis (MTB) is the causative bacterium of tuberculosis, a disease that causes over 
a million deaths worldwide each year and has strains resistant to antibiotics. We wish to better understand 
the underlying mechanisms associated with MTB response under different genetic and environmental 
perturbations of metabolism, which may translate into novel drug targets. As a step toward this goal, we 
have expanded a genome-scale metabolic model for MTB. Our model represents a substantial knowledge 
update, integrating literature-based reaction information from five existing genome-scale metabolic 
reconstructions of MTB and incorporating additional reactions from the literature. Our expanded model 
improves agreement between predicted growth phenotypes and experiments under different carbon and 
nitrogen sources. The simulated growth predictions identify perturbations that generate experimentally 
testable hypotheses of mechanisms underlying perturbation-induced phenotypes in MTB. 
INTRODUCTION 
Tuberculosis remains a major global health challenge with a need for drug development efforts. 
Understanding the metabolism of the causative pathogen, Mycobacterium tuberculosis, plays an 
important role in elucidating how current MTB drugs work [75], uncovering the mechanisms associated 
with the ability of MTB to survive under many different environmental conditions [76], and developing 
novel drug targets [77]. 
Information about metabolic processes in MTB remains largely dispersed across literature sources. 
Efforts to consolidate the extensive literature about the metabolisms of organisms including MTB include 
databases that collect genome annotations (e.g. [78-84]), and integrate information about metabolic 
reactions with enzyme information across multiple species (e.g. [85-88]). Another approach to 
consolidating organism-specific metabolic knowledge is using genome-scale metabolic reconstructions. 
Genome-scale metabolic reconstructions serve both as a knowledge base cataloging known and inferred 
biochemistry of a specific organism, as well as a basis from which quantitative models can be constructed 
to simulate metabolic states of the system [89].  
                                                            
2 This chapter contains material from an article published in Genome Biology. I would like to thank my 
coauthors: Tige Rustad, Kyle Minch, Jessica Winkler, Samuel Hobbs, Mark Hickey, William Brabant, 
Serdar Turkarslan, Nathan Price, Nitin Baliga, and David Sherman. 
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The set of biochemical reactions encapsulated in genome-scale metabolic models can be represented 
mathematically as a set of equations that describe the conversion of each metabolite based on 
stoichiometry. One of the main approaches to performing computations on this model is flux balance 
analysis, which constructs a space of possible reaction states based on physicochemical constraints and 
optimizes to find a steady-state solution [90, 91]. Figure 4 provides a schematic of flux balance analysis 
on a toy metabolic system [90]. The rate of accumulation of each metabolite is a function of the reaction 
fluxes (a measure for the amount of metabolite conversion per unit time) and the exchange fluxes into and 
out of the cell [90]. This system of differential equations can be written in matrix form as a vector 
containing the rate of metabolite accumulation equaling the stoichiometric matrix (S) multiplied by a 
vector of the reaction and exchange fluxes (v). The stoichiometric matrix contains the stoichiometric 
coefficients for each reaction, with the rows representing each metabolite and the columns representing 
each reaction. At steady state, the rate of accumulation is zero, so the matrix equation is simplified to: 
 ܵ ∙ ݒ ൌ 0 (1)
This equation imposes mass balance constraints upon the system, reducing the space of feasible reaction 
fluxes. Additional constraints can be imposed on the reaction fluxes by limiting the lower and upper 
bounds of the flux values [92]: 
 ݈ܾ ൑ ݒ ൑ ݑܾ (2)
The resulting set of equations remains undetermined, representing a large space of feasible solutions that 
obey the constraints imposed. To determine a set of biologically relevant reaction flux solutions, a 
function is defined to represent a biochemical objective that the metabolic system is trying to maximize or 
minimize [90, 91, 93]. Because the metabolic system being simulated is frequently a living cell, the most 
common objective function adopted is to maximize the growth yield of the cell. This is implemented by 
maximizing a component called biomass, which estimates the chemical composition of the cell being 
modeled [94]. The reaction flux solution is determined by optimizing for the objective function within the 
constraints dictated by stoichiometry (Equation 1) and flux bounds (Equation 2) by linear programming 
methods. Flux balance analysis tools have been implemented for MATLAB in the COBRA Toolbox [95, 
96]. 
Given that the simulations of constraint-based metabolic models are rooted in an accurate representation 
of reaction interconnectivity and gene-reaction association information, there have been efforts in 
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multiple organisms, including MTB, to update existing genome-scale metabolic models with improved 
curation of biochemical information [89, 97-99]. Metabolic reconstruction efforts in MTB have resulted 
in five different metabolic models that include substantial sets of non-overlapping reaction information 
[97, 99-102]. Therefore, to further improve the ability to computationally probe and analyze metabolic 
phenotypes in MTB, we generated an updated genome-scale metabolic model by consolidating the 
information from these different MTB models. We used our updated MTB metabolic model to simulate 
growth phenotypes under a range of environmental and genetic perturbations, and further extended our 
model to simulate condition-specific phenotypes by applying constraints learned from gene expression 
data. 
MATERIALS AND METHODS 
Growth phenotype simulations 
Growth phenotype simulations were performed on the genome-scale metabolic models using the flux 
balance analysis tools in the COBRA Toolbox [95, 96]. Growth rates were generated by calculating the 
optimal value of the flux of the biomass generation reaction, which was set as the objective function in 
these simulations. Single gene deletion simulations calculated the growth rates with the reactions that map 
to each individual gene set to have flux rates of zero.  
Evaluating Carbon and Nitrogen Source Utilization Performance 
To evaluate the ability for the metabolic models to predict growth under different environmental 
conditions, we simulated growth under different carbon and nitrogen sources using the COBRA Toolbox 
by adjusting the exchange reaction fluxes to allow input of the desired metabolite. Growth predictions on 
diverse carbon and nitrogen sources were compared to experimental growth condition data reported in 
[99]. We additionally included palmitate, oleate, carbon monoxide, and cholesterol as carbon sources that 
have been experimentally reported elsewhere [103-105]. In our evaluation of carbon and nitrogen 
utilization predictions, we considered only the metabolites that were represented in the genome-scale 
metabolic models. When possible3, we fixed the exchange reaction fluxes of the metabolites that we were 
not adjusting to match the constituents in Sauton’s defined media [106], ensured that removal of the 
nitrogen or carbon source would result in no growth, and determined whether each metabolic model 
would grow in the presence of the different carbon and nitrogen sources. When the carbon source was 
                                                            
3  One of the metabolic models we tested could not grow with Sauton’s media-defined conditions. 
Therefore for this case, we set the exchange fluxes to match the components of Middlebrook 7H9 media 
[106]. 
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varied, the Sauton’s media nitrogen sources were used, and when the nitrogen source was varied, the 
Sauton’s media carbon source was used. 
To compare overall performance, we evaluated the ability of each metabolic model to correctly predict 
growth vs. no growth in the combined set of carbon and nitrogen source metabolites. Performance was 
summarized by sensitivity 


 FNTP
TP
, specificity 


 FPTN
TN
, and the Matthew’s Correlation 
Coefficient (MCC) 



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
)(*)(*)(*)(
**
FNTNFPTNFNTPFPTP
FNFPTNTP
, where TP represented the 
‘true positives’ (the number of metabolites correctly predicted to allow growth), TN represented the ‘true 
negatives’ (the number of metabolites correctly predicted to not allow growth), FP represented the ‘false 
positives’ (the number of metabolites predicted to allow growth but experimentally do not grow), FN 
represented the ‘false negatives’ (the number of metabolites predicted to not allow growth but 
experimentally can grow). 
Evaluating Gene Essentiality Prediction Performance 
To evaluate the ability of the metabolic models to predict gene essentiality, single gene deletion 
simulations on each of the models were compared to an experimental essentiality screening dataset 
generated by Griffin et al. [107]. The Griffin essentiality dataset screened for essential genes from 
transposon mutagenesis libraries by assessing the set of transposon insertions detected after growing the 
pooled transposon mutants for a period of time [107]. The authors summarized their findings with an 
essentiality confidence score for each gene that ranges from 0 to 1 that represents the probability that 
particular gene is non-essential (low confidence scores indicate that a gene is likely essential, and high 
confidence scores indicate that a gene is likely non-essential). We considered genes with Griffin 
essentiality confidence scores of less than 0.1 to be essential, and we evaluated the ability of the 
metabolic models to successfully simulate growth rates that can distinguish these essential genes. 
Predictive performance was visualized by a Receiver Operating Characteristic (ROC) curve and 
quantified by the Area Under the ROC Curve (AUC) using the ‘pROC’ package in R [108]. 
Condition-specific metabolic models 
Condition-specific metabolic models were generated from the genome-scale metabolic models and 
condition-specific gene expression data using the COBRA Toolbox implementation of the iMAT 
algorithm [96, 109, 110]. We used a large microarray dataset measuring the gene expression profile after 
  25
induction of TF overexpression [111] to generate iMAT models that represented the metabolic state of 
each TF overexpression condition. For each TF, the overexpression microarray data were binarized such 
that a gene was designated ‘ON’ if it had a positive fold change value in at least 75% of the samples, and 
was designated as ‘OFF’ otherwise. These binarized values were then used as input to generate a 
condition-specific iMAT model and reaction flux profile from the COBRA Toolbox implementation of 
iMAT [96, 109, 110]. The growth ratio of each TF overexpression condition was calculated by taking the 
ratio of growth rate derived from the iMAT model flux profile and the growth rate simulated from the 
wild-type model. 
RESULTS 
Comparing Existing Metabolic Models of MTB 
The first metabolic model for MTB was constructed for the mycolic acid pathway [112], which generated 
several potential drug targets based on gene deletion simulations. Since this initial effort, several genome-
scale metabolic models for MTB have been constructed (see Table 2). The first two genome-scale 
metabolic models were GSMN-TB, reconstructed by Beste et al. [100], and iNJ661, which was 
reconstructed by Jamshidi et al [101]. GSMN-TB was constructed using a genome scale metabolic model 
for the related bacteria Streptomyces coelicolor. Reactions in the S. coelicolor model catalyzed by 
enzymes that had orthologs in MTB were directly included into GSMN-TB. The remaining reactions 
included in GSMN-TB were taken from the KEGG and BioCyc databases, as well as literature sources 
[100]. The authors of GSMN-TB released an updated model, called GSMN-TB1.1, in 2013, which 
included “corrections” to reactions that exist in GSMN-TB as well as additional reactions that partially 
describe the cholesterol catabolism pathway [99].  
In contrast, the iNJ661 model was based primarily on the genome annotation of the MTB strain H37Rv 
from the CMR database [101]. The reactions referenced in the genome annotation and collected from 
TubercuList, KEGG, and the SEED databases were included into the iNJ661 model, and gaps in pathways 
were filled by reactions taken from the literature [101]. The iNJ661m model was largely based on iNJ661, 
and it included updated pathways associated with energy metabolism based on information in GSMN-TB, 
KEGG, and literature sources [97].  
Like iNJ661, the HQMtb model was based primarily on genome annotations, but the annotations in this 
case were gathered from five different databases (KEGG, Biocyc, Tuberculist, Pedant, and UniProt) 
[102]. The reactions mapped to these annotations that were validated against literature, the literature-
backed reactions in GSMN-TB, and databases (Tuberculist, WebTB [84], Biocyc, and UniProt) [102].  
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We compared the existing metabolic models by two criteria: 1) model contents and 2) their respective 
abilities to simulate metabolic phenotypes under varying genetic and environmental conditions. GSMN-
TB1.1 captures the effect of the greatest number of metabolic genes (759 genes), which enables the 
broadest scope of genetic perturbations that can be simulated. The model iNJ661m has the greatest 
number of total reactions described (1049 reactions), although GSMN-TB1.1 contains more reactions that 
are based on literature-derived, experimental biochemical evidence (279 reactions in GSMN-TB1.1 vs. 
204 reactions in iNJ661m).  
In evaluating the respective abilities to simulate metabolic phenotypes under varying genetic and 
environmental conditions, we compared GSMN-TB, GSMN-TB1.1, iNJ661, and iNJ661m (the metabolic 
reconstruction HQMtb does not include explicit gene-protein-reaction-associations for all reactions or a 
biomass objective function, which precludes metabolic phenotype simulations by flux balance analysis).  
To compare the ability of the models to correctly simulate growth under different environmental 
conditions, we simulated growth of the four models with different input carbon and nitrogen sources. We 
compared these growth simulations with experimental carbon and nitrogen source growth data from [103-
105] (see Methods for details). We considered only carbon and nitrogen sources that already existed as 
metabolites in the models, which total 51 different carbon sources and 40 different nitrogen sources. Of 
the carbon sources considered, MTB has been experimentally shown to be able to grow with 29 of the 
metabolites as the sole carbon source. Of the nitrogen sources, MTB has been shown to grow with 14 of 
the metabolites as the sole nitrogen source.  
Tables 4-7 list detailed carbon and nitrogen source growth prediction and experiment information, and 
Figure 6 is a graphical comparison of predictive performance of the models. GSMN-TB1.1 and GSMN-
TB can predict the growth rate of MTB under the broadest range of simulated media conditions. GSMN-
TB1.1 correctly predicts an ability to grow with 23 compounds as the sole carbon source and 12 
compounds as the sole nitrogen source (69% sensitivity, 55% specificity for the carbon sources; 86% 
sensitivity, 85% specificity for the nitrogen sources), whereas GSMN-TB can correctly predicts an ability 
to grow with 20 compounds as the sole carbon source and 12 compounds as the sole nitrogen source 
(79% sensitivity, 45% specificity for the carbon sources; 86% sensitivity, 77% specificity for the nitrogen 
sources). In contrast, iNJ661 and iNJ661m correctly predict an ability to grow only on glycerol as the sole 
carbon source, and 10 compounds as the sole nitrogen source (3% sensitivity on carbon sources; 71% 
sensitivity, 88% specificity for the nitrogen sources).  
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To each model’s ability to predict the effect of genetic perturbations, we compared metabolic 
consequences of simulating single gene deletions based on the models GSMN-TB, GSMN-TB1.1, and 
iNJ661, under media conditions stipulated by Griffin et al., and we compared the simulation results to 
corresponding experimental gene essentiality data [107] (we did not include iNJ661m in these 
calculations because the unperturbed model was not able to simulate growth under the Griffin media 
conditions). Figure 7 shows the Receiver Operating Characteristic (ROC) curves evaluating the 
performance of single gene deletion simulations based on the different metabolic models. The highest 
predictive accuracy was achieved with GSMN-TB1.1 (red, AUC = 0.77) and GSMN-TB (green, AUC = 
0.77), with iNJ661 (orange) achieving an AUC = 0.64.  
Given that GSMN-TB1.1 can predict growth phenotypes under the broadest range of environmental 
conditions and genetic perturbations with the greatest accuracy, this model had the most appealing 
properties for simulating growth phenotypes in this study.  
Updating the Metabolic Model of MTB 
Although GSMN-TB1.1 has favorable modeling properties, the models iNJ661 and HQMtb contain 
information on reactions known to be catalyzed by MTB that are not captured in GSMN-TB1.1. To 
consolidate the knowledge base of metabolism represented by a genome-scale metabolic model, we 
updated GSMN-TB1.1 by integrating the gene-associated reactions with literature evidence in iNJ661 and 
HQ-Mtb that were absent from GSMN-TB1.1. The resulting updated metabolic model, iSM-MTB-810, 
expands the consolidated knowledgebase of MTB metabolism represented by the model, with 51 new 
genes and 57 new literature-associated reactions spanning a broad range of metabolic functions (see Table 
3 for full list of reactions added to the model). The updated model has added reactions needed for the 
metabolism of cholesterol, glycogen, and carbon monoxide.  
Evaluating the Predictive Ability of the Updated Metabolic Model 
We evaluated the ability for iSM-MTB-810 to simulate growth under a broad range of media conditions. 
We compared experimentally derived media-specific growth phenotypes with growth phenotypes 
predicted by the metabolic model (see Methods for details). Tables 3-6 list the growth abilities that were 
predicted by iSM-MTB-810 and Figure 6 compares its predictive performance with the other metabolic 
models. The updated model, iSM-MTB-810, correctly predicts an ability to grow with 24 compounds as 
the sole carbon source and 12 compounds as the sole nitrogen source (83% sensitivity, 55% specificity for 
the carbon sources; 86% sensitivity, 81% specificity for the nitrogen sources). Overall, iSM-MTB-810 
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correctly predicts growth in a greater number of carbon and nitrogen sources than the other metabolic 
models (see Figure 6). 
To evaluate the ability of iSM-MTB-810 to predict the growth effects of genetic perturbations, we 
compared single gene deletion growth predictions to the Griffin essentiality data [107] (see Methods for 
details). We found that iSM-MTB-810 predicted gene essentiality with AUC = 0.76, which is comparable 
to the performance of GSMN-TB and GSMN-TB1.1. 
Condition-specific Metabolic Models Predict Transcription Factor Overexpression Growth 
Phenotypes 
To facilitate the prediction of growth phenotypes under conditions other than log-phase growth in defined 
media conditions, additional constraints need to be imposed on the reaction flux bounds to appropriately 
contextualize the metabolic model. One such approach to apply constraints is to impose reaction flux 
bounds based on condition-specific gene expression. We generated condition-specific metabolic models 
based on iSM-MTB-810 and gene expression data measuring the consequence of 196 different 
transcription factor overexpression (TFOE) conditions [111] (see Methods for details). To demonstrate 
the utility of these TFOE-specific models, we compared the model-predicted growth ratios with 
experimentally measured ratio of the uninduced vs. overexpression-induced growth rates. Figure 8 shows 
the measured growth ratios of the TFOE strains, color-coded by whether the corresponding TFOE 
condition-specific metabolic models predicted a growth defect. The TFOE condition-specific metabolic 
models demonstrated a statistically significant predictive ability to identify strains with growth ratio of 
greater than the 90% quantile (corresponding to 2.6 -fold reduction), with an ROC AUC of 0.73 (p < 0.05, 
DeLong’s Method, see Figure 9). The experimental doubling times for TFOE strains predicted to be 
defective were significantly longer than the doubling times for strains predicted to be not defective (p < 
0.05, t-test). This performance is higher than the predictive performance using the number of repressed 
essential metabolic target genes, which could predict growth defects with an AUC of 0.68. Therefore, the 
TFOE data sets contextualize the metabolic model to gain additional physiological insight and predictive 
power. 
DISCUSSION 
In this work, we have reconstructed an updated genome-scale metabolic model for Mycobacterium 
tuberculosis by consolidating high confidence biochemical knowledge from the multiple existing 
metabolic models and from literature based evidence. We have used our updated model, iSM-MTB-810 
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to predict growth phenotypes under multiple environmental and genetic perturbations. Our model can be 
further refined by integrating gene expression data to generate condition-specific models that can simulate 
metabolic phenotypes under transcription factor overexpression conditions.  
We found that, although our updated model, iSM-MTB-810, includes a greater number of genes and 
literature-associated reactions than the other models, it and has an improved predictive ability in 
determining growth phenotypes under differing carbon and nitrogen utilization conditions, it does not 
perform better than GSMN-TB1.1 in predicting growth phenotypes under single gene deletion conditions. 
This result suggests two important implications: (1) updating the model to expand the knowledgebase of 
underlying biochemistry does not necessarily lead to uniformly improved predictive ability, and (2) it is 
sometimes difficult to assess the quality of a metabolic model predictive ability; a particular model may 
perform more favorably for a subset of predictions and less favorably on other predictions.  
The fact that iSM-MTB-810 expands the knowledgebase without uniformly improving the ability to 
predict metabolic phenotypes underscores the need to delineate the dual purposes for such genome-scale 
models of metabolism. Assembling a reconstruction of metabolism that represents as much of the known 
biochemistry as possible is useful and its own capacity as a consolidated database and as a means to study 
the topology of the metabolic network. 
iSM-MTB-810 performed better than the other models on predicting growth phenotypes based on carbon 
and nitrogen source utilization but performed comparably to GSMN-TB1.1 on predicting single gene 
deletion essentiality, suggesting that predictive performance is not a uniform feature. The field of 
constraint-based modeling of metabolism primarily uses single-gene deletion essentiality to evaluate the 
predictive ability of its models. However, our results show that high performance in essentiality 
predictions under a particular media condition does not guarantee high performance at predicting other 
metabolic phenotypes. This stresses the need to assess model predictions using multiple tests, as well as 
tests that are tailored to the specific application of study. 
Besides predicting the effects of environmental and metabolic gene perturbations, iSM-MTB-810 was 
also successful at predicting transcription factor overexpression growth phenotypes when coupled with 
condition-specific metabolic flux constraints derived from gene expression. The success of the condition-
specific metabolic model predictions suggests that, provided that condition-specific metabolic flux 
constraints can be effectively generated, applying the metabolic model can probe the metabolism of a 
broad range of states, including the consequences of regulatory perturbations. 
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FIGURES AND TABLES 
 
Figure 4. Overview of flux balance analysis. (a) The toy metabolic system being described has three internal 
reactions (ν1-ν4; ν2 and ν3 describe a reversible reaction), which involves three metabolites (A-C) that are transported 
into and out of the system with three exchange reactions (b1-b3). These reactions can be represented as a system of 
differential equations and in matrix form, which defines a space of possible reaction flux solutions. This solution 
space can be further constrained with lower and upper bounds on each reaction flux value. To yield a biologically 
relevant solution, I can optimize for an objective function to find the fluxes that yield the optimum values for the 
desired objective. Reprinted from Volume 14, Issue 5, Kauffmann KJ et al., “Advances in flux balance analysis,” 
pages 491-496, Copyright (2003), with permission from Elsevier [90]. 
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Figure 5. Comparison of properties of genome-scale metabolic reconstructions of MTB. (A) Comparison of the 
number of metabolic genes described by each metabolic model. (B) Comparison of the number of total reactions and 
the number of reactions with literature evidence described by each metabolic model. 
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Figure 6. Comparison of ability to predict growth in different carbon and nitrogen sources. Performance is 
evaluated by the Matthews Correlation Coefficient (see Methods for description) calculated by combining the 
carbon and nitrogen source predictions together (i.e. considering all 91 metabolite predictions). GSMN-TB and 
GSMN-TB1.1 perform better than iN661m and iNJ661, and iSM-MTB-810 improves upon GSMN-TB and GSMN-
TB1.1. 
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Figure 7. Comparison of ROC curves evaluating performance of gene essentiality predictions for different 
MTB metabolic models. The model iNJ661 (orange) has an AUC of 0.64. The models GSMN-TB (green) and its 
updated version GSMN-TB1.1 (red) have substantially improved performance, with AUCs of 0.77. The updated 
model, iSM-MTB-810 has a performance comparable to GSMN-TB1.1 (blue), with an AUC of 0.76. 
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Figure 8. Growth defect predictions of transcription factor overexpression conditions. The bar heights 
represent the experimentally measured doubling time ratios between the overexpression induced condition and the 
uninduced condition, with doubling time ratios greater than five truncated. The bars are color-coded according to 
whether the condition-specific metabolic models predicted a growth defect in the overexpression of that TF (red = 
defect, blue = no defect). The black dashed line represents a cutoff threshold for growth defect set at the 90th 
percentile of doubling time ratios (corresponding to a ratio of 2.6). 
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Figure 9. ROC curves evaluating performance of predicting transcription factor overexpression growth 
defects. The predictive performance of the condition-specific metabolic models (blue) yields an AUC of 0.73, which 
is higher than the performance of using the number of repressed essential metabolic genes as a predictor (green, 
AUC = 0.68). 
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Table 2: Summary of existing genome-scale metabolic models for in vitro MTB. 
Genome-scale 
metabolic model 
Reference Number of Genes 
Number of 
Reactions 
Number of 
Metabolites 
GSMN-TB [100] 726 856 645 
GSMN-TB 1.1 [99] 759 876 667 
iNJ661 [101] 661 1025 826 
iNJ661m [97] 663 1049 838 
HQMtb [102] 686 607 734 
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Table 3. Summary of reactions added to GSMN-TB1.1 to generate iSM-MTB-810 
Reaction Name Reaction Formula 
Gene Protein 
Reaction 
Associations 
Reaction 
Pathway Reference 
3B-Hydroxysteroid 
Dehydrogenase 
H[c] + NAD[c] + CHOLESTEROL[c]  -> NADH[c] + 
CHOLESTENONE[c] Rv1106c 
Cholesterol 
degradation [105] 
Androst_HsaD 49DSHA[c]  -> DOHNAA[c] + HYDROXYHEXADIENOATE[c] 
Cholesterol 
degradation [107, 113, 114] 
Androst_HsaEFG HYDROXYHEXADIENOATE[c]  -> PYR[c] + PROPANOATE[c]    Cholesterol degradation [107, 113, 114] 
Bisnorchol_Ltp2 3OXO23_24BISNORCHOL4EN17OL22OYL_COA[c]  -> PROPIONYLCOA[c] + 4ADSD[c] Rv3540c 
Cholesterol 
degradation [107, 113, 114] 
Bisnorchol_MaoC 
3OXO23_24BISNORCHOL4_17DIEN22OYL_COA[c]  
-> 
3OXO23_24BISNORCHOL4EN17OL22OYL_COA[c] 
Rv3541c or 
Rv3542c 
Cholesterol 
degradation [107, 113, 114] 
Bisnorchol_fadA5 
COA[c] + 3_22DIOXOCHOL4EN24OYL_COA[c]  -> 
ACCOA[c] + 
3_OXO_23_24BISNORCHOL4EN22OYL_COA[c] 
Rv3546 Cholesterol degradation [107, 113, 114] 
Bisnorchol_fadE 
FAD[c] + 
3_OXO_23_24BISNORCHOL4EN22OYL_COA[c]  -> 
FADH2[c] + 
3OXO23_24BISNORCHOL4_17DIEN22OYL_COA[c] 
Rv3544c and 
Rv3543c 
Cholesterol 
degradation [107, 113, 114] 
Chol_echA 3_OXOCHOL4_22DIEN24OYL_COA[c]  -> 22HYDROXY3OXOCHOL4EN24OYL_COA[c] 
Rv1071c or 
Rv3538 
Cholesterol 
degradation [107, 113, 114] 
Chol_fadA5 
COA[c] + 3_24DIOXOCHOLEST4EN26OYL_COA[c]  
-> PROPIONYLCOA[c] + 
3_OXOCHOL4EN24OYL_COA[c] 
Rv3546 Cholesterol degradation [107, 113, 114] 
Chol_fadB 
NAD[c] + 
22HYDROXY3OXOCHOL4EN24OYL_COA[c]  -> 
H[c] + NADH[c] + 
3_22DIOXOCHOL4EN24OYL_COA[c] 
Rv0860 Cholesterol degradation [107, 113, 114] 
Chol_fadE FAD[c] + 3_OXOCHOL4EN24OYL_COA[c]  -> FADH2[c] + 3_OXOCHOL4_22DIEN24OYL_COA[c] 
Rv0244c or 
Rv3274c or 
Rv3544c or 
Rv3543c or 
Rv3560c or 
Rv3563 or 
Rv3564 or 
Rv3573c 
Cholesterol 
degradation [107, 113, 114] 
Chol_echA 3_OXOCHOL4_22DIEN24OYL_COA[c]  -> 22HYDROXY3OXOCHOL4EN24OYL_COA[c] 
Rv1071c or 
Rv3538 
Cholesterol 
degradation [107, 113, 114] 
Chol_fadA5 
COA[c] + 3_24DIOXOCHOLEST4EN26OYL_COA[c]  
-> PROPIONYLCOA[c] + 
3_OXOCHOL4EN24OYL_COA[c] 
Rv3546 Cholesterol degradation [107, 113, 114] 
Chol_fadB 
NAD[c] + 
22HYDROXY3OXOCHOL4EN24OYL_COA[c]  -> 
H[c] + NADH[c] + 
3_22DIOXOCHOL4EN24OYL_COA[c] 
Rv0860 Cholesterol degradation [107, 113, 114] 
Chol_fadE FAD[c] + 3_OXOCHOL4EN24OYL_COA[c]  -> FADH2[c] + 3_OXOCHOL4_22DIEN24OYL_COA[c] 
Rv0244c or 
Rv3274c or 
Rv3544c or 
Rv3543c or 
Rv3560c or 
Rv3563 or 
Rv3564 or 
Rv3573c 
Cholesterol 
degradation [107, 113, 114] 
Cholesterol_Cyp125 CHOLESTENONE[c]  -> 3OXOCHOLEST4EN26OATE[c] 
Rv3545c or 
Rv3518c 
Cholesterol 
degradation [107, 113, 114] 
Cholesterol_FadD 
ATP[c] + 2 H[c] + COA[c] + 
3OXOCHOLEST4EN26OATE[c]  -> ADP[c] + 2 
PPI[c] + 3OXOCHOLEST4EN26OYL_COA[c] 
Rv3515c or 
Rv1193 
Cholesterol 
degradation [107, 113, 114] 
bDG6P_Transport -> bDG6P[c]   Transport [99] 
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Table 3 (cont.) 
Reaction Name Reaction Formula 
Gene Protein 
Reaction 
Associations 
Reaction 
Pathway Reference 
Cholesterol_FadE 
FAD[c] + 3OXOCHOLEST4EN26OYL_COA[c]  -> 
FADH2[c] + 
3OXOCHOLEST4_24DIEN26OYL_COA[c] 
Rv0244c or 
Rv3274c or 
Rv3544c or 
Rv3543c or 
Rv3560c or 
Rv3563 or 
Rv3564 or 
Rv3573c 
Cholesterol 
degradation [107, 113, 114] 
Cholesterol_echA 3OXOCHOLEST4_24DIEN26OYL_COA[c]  -> 24HYDROXY3OXOCHOLEST4EN26OYL_COA[c] 
Rv1071c or 
Rv3538 
Cholesterol 
degradation [107, 113, 114] 
Cholesterol_fadB 
NAD[c] + 
24HYDROXY3OXOCHOLEST4EN26OYL_COA[c]  
-> H[c] + NADH[c] + 
3_24DIOXOCHOLEST4EN26OYL_COA[c] 
Rv0860 Cholesterol degradation [107, 113, 114] 
DOHNAA_carboxylate HMOOI-OXOPROPANOYL_COA[c]  -> ACCOA[c] + HMOOI-CARBOXYLATE[c]    Cholesterol degradation   
DOHNAA_fadD3 ATP[c] + COA[c] + DOHNAA[c]  -> PPI[c] + AMP[c] + DOHNA_COA[c]    Cholesterol degradation   
DOHNAA_fadE30 FAD[c] + HYDROXY-DOHNA_COA[c]  -> FADH2[c] + HMOOI-PROPENOYL_COA[c] 
Cholesterol 
degradation   
DOHNAA_hydroxy H[c] + NADPH[c] + DOHNA_COA[c]  -> NADP[c] + HYDROXY-DOHNA_COA[c]    Cholesterol degradation   
DOHNAA_hydroxy2 HMOOI-PROPENOYL_COA[c]  -> HMOOI-HYDROXYPROPANOYL_COA[c] 
Cholesterol 
degradation   
DOHNAA_oxo 
NAD[c] + HMOOI-
HYDROXYPROPANOYL_COA[c]  -> H[c] + 
NADH[c] + HMOOI-OXOPROPANOYL_COA[c] 
   Cholesterol degradation   
HMOOI-CARBOX-
Transport HMOOI-CARBOXYLATE[c]  <=> Transport   
COxt <=> CO[c]   Transport [115] 
GLUCANBRANCH LINEAR-GLUCAN[c]  -> GLYCOGEN[c] Rv1326c Glycogen metabolism [116, 117] 
MALTOKINASE ATP[c] + MLT[c]  -> ADP[c] + MLT1P[c] Rv0127 Glycogen metabolism [118] 
MLT1P MLT1P[c]  -> PI[c] + LINEAR-GLUCAN[c] Rv1327c Glycogen metabolism [119] 
Pantothenate_Transpo
rt -> PNTO[c]  Transport [120] 
R-c12-enoyl-
CoAdehydratase 
HYDROXYDODECANOYL_COA[c]  -> 
DODECENOYL_COA[c] 
Rv3389c and 
Rv1484 
Fatty Acid 
Metabolism [121] 
R-c12-enoyl-
CoAhydratase 
DODECENOYL_COA[c]  -> 
HYDROXYDODECANOYL_COA[c] Rv3389c 
Fatty Acid 
Metabolism [121] 
R-c14-enoyl-
CoAdehydratase 
HYDROXYTETRADECANOYL_COA[c]  -> 
TETRADECENOYL_COA[c] 
Rv3389c and 
Rv1484 
Fatty Acid 
Metabolism [121] 
R-c14-enoyl-
CoAhydratase 
TETRADECENOYL_COA[c]  -> 
HYDROXYTETRADECANOYL_COA[c] Rv3389c 
Fatty Acid 
Metabolism [121] 
R-c16-enoyl-
CoAdehydratase 
HYDROXYHEXADECANOYL_COA[c]  -> 
HEXADECENOYL_COA[c] 
Rv3389c and 
Rv1484 
Fatty Acid 
Metabolism [121] 
R-c16-enoyl-
CoAhydratase 
HEXADECENOYL_COA[c]  -> 
HYDROXYHEXADECANOYL_COA[c] Rv3389c 
Fatty Acid 
Metabolism [121] 
R116 3 NADH[c] + NO2[c]  -> 3 NAD[c] + NH3[c] Rv0252 or Rv0253 
Nitrogen 
Metabolism [122] 
TREX GLYCOGEN[c]  -> MALTODEXTRIN[c] Rv1564c Glycogen metabolism [119] 
TREY MALTODEXTRIN[c]  -> MALTOOLIGOSYL-TREHALOSE[c] Rv1563c 
Glycogen 
metabolism [117] 
TREZ MALTOOLIGOSYL-TREHALOSE[c]  -> TRE[c] Rv1562c Glycogen metabolism [117] 
UDPP UDCPDP[c]  <=> H[c] + PI[c] + UDCPP[c] Rv2136c Peptidoglycan Metabolism [123] 
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Table 3 (cont.) 
Reaction Name Reaction Formula 
Gene Protein 
Reaction 
Associations 
Reaction 
Pathway Reference 
iNJ661_ACGAMT UDPNAG[c] + UDCPP[c]  -> UMP[c] + UNAGA[c] Rv1302 Peptidoglycan Metabolism [124] 
iNJ661_CDAPPA160 CDPDG[c]  -> 2 H[c] + CMP[c] + PA[c] Rv2289 Membrane Metabolism [101] 
iNJ661_CODH3 FERI[c] + 2 CO[c]  -> 2 H[c] + 2 CO2[c] + FERO[c] 
Rv0373c and 
Rv0374c and 
Rv0375c 
Redox 
Metabolism [115] 
iNJ661_DESAT18 
H[c] + NADPH[c] + O2[c] + 
OCTADECANOYL_COA[c]  -> NADP[c] + 
9_OCTADECENOYL_COA[c] 
Rv1094 or 
Rv0824c 
Fatty Acid 
Metabolism [125] 
iNJ661_FASM1601 
H[c] + 2 NADPH[c] + SMMALONYLCOA[c] + 
HEXADECANOATE[c]  -> NADP[c] + CO2[c] + 
COA[c] + METHYL_OCTADECANOATE[c] 
Rv1662 or 
Rv1663 
Membrane 
Metabolism [126] 
iNJ661_FASM180 
15 H[c] + 10 NADPH[c] + SMMALONYLCOA[c] + 4 
MALCOA[c] + OCTANOATE[c]  -> 10 NADP[c] + 5 
CO2[c] + 5 COA[c] + TUBERCULOSTEROYL_ACP[c] 
Rv1662 or 
Rv1663 
Membrane 
Metabolism [126] 
iNJ661_FASM1801 
3 H[c] + 2 NADPH[c] + SMMALONYLCOA[c] + 
METHYL_OCTADECANOATE[c]  -> 2 NADP[c] + 
CO2[c] + COA[c] + DMARACH[c] 
Rv1662 or 
Rv1663 
Membrane 
Metabolism [126] 
iNJ661_FASM2001 
H[c] + 2 NADPH[c] + SMMALONYLCOA[c] + 
DMARACH[c]  -> 2 NADP[c] + CO2[c] + COA[c] + 
TMBHN[c] 
Rv1662 or 
Rv1663 
Membrane 
Metabolism [126] 
iNJ661_FASM2002 
3 H[c] + 2 NADPH[c] + SMMALONYLCOA[c] + 
OCTADECANOATE[c]  -> 2 NADP[c] + CO2[c] + 
COA[c] + MARACH[c] 
Rv1662 or 
Rv1663 
Membrane 
Metabolism [126] 
iNJ661_FCOAH2 FORCOA[c]  -> H[c] + FOR[c] + COA[c] Rv2605c Redox Metabolism [101] 
iNJ661_GLCP PI[c] + GLYCOGEN[c]  -> G1P[c] Rv1328 Glycogen metabolism [117] 
iNJ661_GLCS1 ADPGLC[c]  -> H[c] + ADP[c] + LINEAR-GLUCAN[c] Rv1212c or Rv3032 
Glycogen 
metabolism [117] 
iNJ661_GLGC ATP[c] + H[c] + G1P[c]  -> PPI[c] + ADPGLC[c] Rv1213 Glycogen metabolism [117] 
iNJ661_GLYCL NAD[c] + THF[c] + GLY[c]  -> H[c] + NADH[c] + CO2[c] + METTHF[c] + NH3[c] Rv1826 
Folate 
Metabolism [101] 
iNJ661_GTMLT ALA[c] + GTHRD[c]  -> CGLY[c] + GLUALA[c] Rv0773c and Rv2394 
Other Amino 
Acid 
Metabolism 
[127] 
iNJ661_MALTabc ATP[c]  -> H[c] + ADP[c] + PI[c] + MLT[c] 
Rv1236 and 
Rv1237 and 
Rv1238 
Transport [128] 
iNJ661_MI3PP MI3PD[c]  -> PI[c] + MI[c] Rv1604 Peptidoglycan Metabolism [129] 
iNJ661_MI4PP MI4PD[c]  -> PI[c] + MI[c] Rv1604 Peptidoglycan Metabolism [129] 
iNJ661_MYC1CYC1 SAM[c] + MEROACIDACP[c]  -> H[c] + SAH[c] + MEROACIDCYC1ACP[c] Rv0470c 
Fatty Acid 
Metabolism [130] 
iNJ661_MYC1CYC2 SAM[c] + MMEROACIDACP[c]  -> H[c] + SAH[c] + MMEROACIDCYC1ACP[c] Rv0470c 
Fatty Acid 
Metabolism [130] 
iNJ661_MYC1CYC3 SAM[c] + KMEROACIDACP[c]  -> H[c] + SAH[c] + KMEROACIDCYC1ACP[c] Rv0470c 
Fatty Acid 
Metabolism [130] 
iNJ661_MYCTR NADP[c] + MYCOTHIOL[c]  <=> H[c] + NADPH[c] + MYCOTHIOL_S_CONJUGATE[c] Rv2855 
Cofactor, 
mycothiol 
biosynthesis 
[131] 
iNJ661_PREPHACPH PREPHTHACP[c]  -> H[c] + ACP[c] + PREPHTH[c] Rv2928 Membrane Metabolism [132] 
iNJ661_PREPPACPH PREPPHTHACP[c]  -> H[c] + ACP[c] + PREPPHTH[c] Rv2928 Membrane Metabolism [132] 
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Table 4. Summary of Growth Predictions for Metabolites that Can Be Used as Sole Carbon Source. ‘0’ 
indicates no growth, and ‘1’ indicates growth either measured experimentally (column 2) or as predicted by the 
metabolic models (column 3-6). Note that iNJ661 and iNJ661m yielded the same growth predictions. 
Carbon sources Experiment iSM-MTB-810 GMSN-TB1.1 GSMN-TB iNJ661/iNJ661m 
2-Oxoglutarate 1 1 1 1 0 
Acetate 1 1 1 1 0 
Acetoacetic Acid 1 0 0 0 0 
Caproic Acid 
(hexanoate) 1 1 1 1 0 
Cholesterol 1 1 0 0 0 
Citrate 1 1 1 1 0 
D-Glucose 1 1 1 1 0 
D-Mannose 1 1 1 1 0 
D-Trehalose 1 1 1 1 0 
Glycerol 1 1 1 1 1 
Glycine 1 1 1 0 0 
L-Alanine 1 1 1 1 0 
L-Arginine 1 0 0 0 0 
L-Asparagine 1 1 1 0 0 
L-Aspartic Acid 1 1 1 1 0 
L-Glutamate 1 1 1 1 0 
L-Isoleucine 1 1 1 1 0 
L-Lactate 1 1 1 1 0 
L-Malic Acid 1 1 1 1 0 
L-Proline 1 1 1 1 0 
L-Serine 1 1 1 0 0 
Oleate (9-Octadecenoate) 1 1 1 1 0 
Palmitate 
(Hexadecanoate) 1 1 1 1 0 
Propanoate 1 1 1 1 0 
Pyruvate 1 1 1 1 0 
Succinate 1 1 1 1 0 
Caprylate (Octanoate) 1 0 0 0 0 
Mycolic Acid 1 0 0 0 0 
Carbon Monoxide 1 0 0 0 0 
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Table 5. Summary of Growth Predictions for Metabolites that Cannot Be Used as Sole Carbon Source. ‘0’ 
indicates no growth, and ‘1’ indicates growth either measured experimentally (column 2) or as predicted by the 
metabolic models (column 3-6). Note that iNJ661 and iNJ661m yielded the same growth predictions. 
Carbon sources Experiment iSM-MTB-810 GMSN-TB1.1 GSMN-TB iNJ661/iNJ661m 
2-Deoxyadenosine 0 0 1 0 0 
Adenosine 0 0 1 0 0 
D-Cellobiose 0 0 0 1 0 
D-Fructose 0 1 1 1 0 
D-Galactose 0 1 1 1 0 
D-Glucose-1-phosphate 0 0 1 0 0 
D-Ribose 0 1 1 1 0 
D,L -α-Glycerol 
phosphate 0 1 0 1 0 
Formic Acid 0 0 0 0 0 
Glycolic Acid 0 1 1 1 0 
Inosine 0 0 1 0 0 
L-Histidine 0 0 0 0 0 
L-Leucine 0 0 0 0 0 
L-Lysine 0 0 0 0 0 
L-Methionine 0 0 0 0 0 
L-Ornithine 0 1 0 0 0 
L-Phenylalanine 0 0 0 0 0 
L-Threonine 0 1 1 1 0 
L-Valine 0 1 1 1 0 
Maltose 0 1 1 1 0 
Sucrose 0 1 1 1 0 
Uridine 0 0 0 0 0 
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Table 6. Summary of Growth Predictions for Metabolites that Can Be Used as Sole Nitrogen Source. ‘0’ 
indicates no growth, and ‘1’ indicates growth either measured experimentally (column 2) or as predicted by the 
metabolic models (column 3-7). 
Nitrogen sources Experiment iSM-MTB-810 GMSN-TB1.1 GSMN-TB iNJ661 iNJ661m 
Ammonia 1 1 1 1 1 1 
Glycine 1 1 1 1 1 1 
L-Alanine 1 1 1 1 1 1 
L-Arginine 1 0 1 0 1 1 
L-Asparagine 1 1 1 1 1 1 
L-Aspartic Acid 1 1 1 1 1 1 
L-Cysteine 1 0 0 0 0 0 
L-Glutamic Acid 1 1 1 1 1 1 
L-Glutamine 1 1 1 1 0 0 
L-Isoleucine 1 1 1 1 0 0 
L-Ornithine 1 1 0 1 1 1 
L-Proline 1 1 1 1 1 1 
L-Serine 1 1 1 1 1 1 
L-Valine 1 1 1 1 0 0 
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Table 7. Summary of Growth Predictions for Metabolites that Can Be Used as Sole Nitrogen Source. ‘0’ 
indicates no growth, and ‘1’ indicates growth either measured experimentally (column 2) or as predicted by the 
metabolic models (column 3-7). 
Nitrogen sources Experiment iSM-MTB-810 GMSN-TB1.1 GSMN-TB iNJ661 iNJ661m 
Adenine 0 0 1 0 0 0 
Adenosine 0 0 1 0 0 0 
D-Alanine 0 1 1 1 1 1 
D-Glutamic Acid 0 0 0 0 0 0 
Guanine 0 0 0 0 0 0 
Guanosine 0 0 0 0 0 0 
Inosine 0 0 0 0 0 0 
L-Citrulline 0 0 0 0 0 0 
L-Histidine 0 0 0 0 0 0 
L-Homoserine 0 0 1 0 0 0 
L-Leucine 0 0 0 0 0 0 
L-Lysine 0 0 0 0 0 0 
L-Methionine 0 0 0 0 0 0 
L-Phenylalanine 0 0 0 0 1 1 
L-Threonine 0 1 1 1 0 0 
L-Tryptophan 0 0 0 0 1 1 
L-Tyrosine 0 0 0 0 0 0 
N-Acetyl-D,L 
Glutamic Acid 0 0 0 0 0 0 
Nitrate 0 0 0 0 0 1 
Nitrite 0 1 0 0 0 1 
Uracil 0 0 0 0 0 0 
Urea 0 1 1 1 0 0 
Uridine 0 0 0 0 0 0 
Xanthine 0 0 0 0 0 0 
Xanthosine 0 0 0 0 0 0 
γ-Amino-N Butyric 
Acid 0 1 0 1 0 0 
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CHAPTER 4: Integrative Regulatory-Metabolic Modeling of 
Mycobacterium tuberculosis4 
ABSTRACT 
Mycobacterium tuberculosis (MTB) is the causative bacterium of tuberculosis, a disease that causes over 
a million deaths worldwide each year and has strains resistant to antibiotics. We wish to better understand 
the underlying mechanisms associated with MTB response under different genetic and environmental 
perturbations of metabolism and regulation, which may translate into novel drug targets. As a step toward 
this goal, we have expanded a genome-scale regulatory-metabolic model for MTB using the Probabilistic 
Regulation of Metabolism (PROM) framework. Our model represents a substantial knowledge base 
update, incorporating a recent ChIP-seq based transcription factor binding network containing 2556 
interactions linking 104 transcription factors (TFs) to 647 metabolic genes, as well as an expanded 
metabolic model that can predict growth in a broad range of environmental conditions. Our expanded 
model improves agreement between predicted growth effects of TF knockouts and gene essentiality 
experiments compared to the original PROM MTB model and can successfully predict growth defects 
associated with TF overexpression. The simulated growth predictions identify perturbations that lead to 
condition-specific growth defects, generating experimentally testable hypotheses of mechanisms 
underlying perturbation-induced phenotypes in MTB. 
INTRODUCTION 
Tuberculosis remains a major global health challenge with a need for novel drug development efforts. 
One of the difficulties of treating tuberculosis arises because the causative pathogen, Mycobacterium 
tuberculosis displays the ability to tune its physiology to adapt and survive in a broad range of conditions, 
altering its susceptibility to different drugs in the process. Understanding transcriptional regulatory 
processes and how regulation interfaces with metabolism in MTB will give insight into the underlying 
mechanisms that are associated with its adaptation to different environmental conditions. 
To date, the three major strategies for incorporating regulatory information into metabolism have 
involved: (1) modifying the objective function to impose an implicit regulatory goal [93, 113], (2) 
                                                            
4 This chapter contains materials from an article in press at Nature Communications. Thanks go to my 
coauthors: Kyle Minch, Tige Rustad, Eliza Peterson, Jessica Winkler, David Reiss, Mark Hickey, 
William Brabant, Bill Morrison, Serdar Turkarslan, Chris Mawhinney, James Galagan, Nathan Price, 
Nitin Baliga, and David Sherman. 
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overlaying gene expression information to impose condition-specific flux constraints on the metabolic 
model, and (3) integrating transcriptional regulatory information directly with the metabolic model.  
In the absence of explicit regulatory interaction information, overlaying gene expression onto metabolic 
models has been used as a proxy to further constrain the space of possible metabolic flux states. Mapping 
gene expression onto a genome-scale has involved blocking reactions that were catalyzed by enzymes 
with low expression (e.g. GIMME and MADE) [113, 114], setting the objective function to maximize the 
number of reactions catalyzed by non-expressing enzymes that have zero flux and the number of reactions 
catalyzed by expressing enzymes that have non-zero flux (e.g. iMAT) [109, 110], or relating the reaction 
flux bounds directly to the relative expression of the gene that codes for the catalyzing enzyme (e.g. E-
FLUX) [115]. These methods do not explicitly account for the specific mechanisms involved in 
transcriptional regulation; rather, they apply the effects of perturbations apparent in the gene expression 
data directly as reaction constraints upon metabolic model. 
Integrating information about regulation and metabolism has also been attempted by taking advantage of 
known regulatory interactions between transcription factors, metabolic target genes, and environmental 
conditions. Most of these approaches (e.g. rFBA and SR-FBA) typically involve manually defining a set 
of regulatory rules that depend on both the presence of specific transcription factors and metabolites as 
Boolean logic statements based from literature information [24-26, 116]. While these Boolean 
relationships can be formulated to describe combinatorial regulation and regulatory feedback triggered by 
the presence of metabolites, a significant drawback to these manually generated rules is the difficulty to 
scale the rule generation process to capture the complete set of regulatory interactions. Regulatory 
constraints have also been interfaced in a semi-automated manner with the Probabilistic Regulation of 
Metabolism framework (PROM) [23]. PROM simulates the effect of transcription factor knockouts on 
metabolism by learning the conditional probability that a transcription factor knockout will block the 
expression of a corresponding metabolic target gene. The resulting probability is mapped onto the 
reactions catalyzed by the protein encoded by the target gene as a soft constraint on the reaction flux 
bounds. Notably, the first integrated metabolic-regulatory model for MTB was constructed using PROM 
[23]. 
In this work, we present a significantly updated regulatory-metabolic model for MTB that encapsulates a 
greatly expanded knowledgebase of underlying metabolic and regulatory mechanism and that can 
generate phenotype predictions for a much broader set of transcription factors exposed to a greater range 
of environmental and genetic perturbations. While much room for improvement remains, we found 
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significant agreement between predictions and experimental datasets assessing gene essentiality and 
growth defects upon transcription factor over-expression. 
MATERIALS AND METHODS 
Modifying PROM to predict transcription factor overexpression 
The original PROM approach to estimating the influence of a regulatory interaction in the event of a TF 
knockout was to calculate from a gene expression dataset the conditional probability that a target gene 
was ‘ON’ in the absence of the transcription factor:  
 
P(Gene = ON | TF = OFF) ≈ 
OFFTFwithsamplesofNumber
OFFTFANDONGenewithsamplesofNumber

  
(3)
The expression threshold that delineated between the ‘ON’ and ‘OFF’ states could be either set externally 
or calculated to be a desired quantile from the input expression data. The conditional probabilities were 
then used to constrain the maximal fluxes of the reactions that the target genes were annotated to catalyze 
in the metabolic component of the model. 
To predict the regulatory effects of TF overexpression, we adapted the conditional probability calculation 
to estimate the probability that a target gene was ‘ON’ upon the overexpression of the transcription factor: 
 P(Gene = ON | TF = OVEREXPRESS) ≈ 
SOVEREXPRESTFwithsamplesofNumber
SOVEREXPRESTFANDONGenewithsamplesofNumber

  (4)
This formulation required setting two expression thresholds: one that delineated between ‘ON’ and ‘OFF’ 
states, and another that delineated between ‘ON’ and ‘OVEREXPRESS.’ It is important to note also that 
this model only took into account the effect of genes that are repressed by transcription factors. The 
effects of target genes that were activated by the overexpression of a transcription factor fell outside the 
scope of this model. 
Sampling-based inference of regulatory interaction influences 
Given that the calculation of the conditional probabilities is dependent on the gene expression dataset 
being used, we used a sampling approach to estimate the uncertainty of the conditional probabilities. The 
microarray dataset measuring gene expression profiles of individual overexpression perturbations of 206 
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TF [111] that we used for our conditional probability estimation was particularly suited for our sampling 
approach because it included at least three biological replicates measuring the overexpression of each TF. 
Therefore, we sampled the dataset 500 times by randomly selecting for each TF three replicates 
measuring the overexpression and calculated the conditional probability from the resulting assembled 
data. 
Generating iMAT models for transcription factor overexpression 
We compared the ability of PROM to predict transcription factor overexpression phenotypes with the 
predictive ability of using condition-specific metabolic models generated by the iMAT algorithm [109, 
110]. We used the TF overexpression microarray dataset to generate iMAT models to simulate the 
metabolic state of each TF overexpression condition [111]. For each TF, the overexpression microarray 
data were binarized such that a gene was designated ‘ON’ if it had a positive fold change value in at least 
75% of the samples, and was designated as ‘OFF’ otherwise. These binarized data were then used to 
generate a condition-specific iMAT model and reaction flux profile from the COBRA Toolbox 
implementation of iMAT [96, 109, 110]. The growth ratio of each TF overexpression condition was 
calculated by taking the ratio of growth rate derived from the iMAT flux profile and the growth rate 
simulated from the wild-type model, iSM-MTB-810. 
Evaluating the predictive performance of predictions 
Predictions by PROM or iMAT on whether a particular TF perturbation results in a growth defect were 
compared against experimental data (Griffin gene essentiality data for knockouts and experimental 
doubling time ratio data for overexpression). The experimental data were used to separate the TFs into 
two groups: those that have a defect when perturbed and those that do not. Performance was evaluated 
based on how well the prediction method could correctly separate the TFs into these groups, where a true 
positive was a TF that was correctly predicted to cause a defect, and a true negative was a TF that was 
correctly predicted not to cause a defect. Predictive performances were summarized by Receiver 
Operating Characteristic (ROC) curves, which were visualized and analyzed in the R package “pROC” 
[108]. 
Estimating the confidence of PROM predictions 
To estimate a confidence score for how likely the PROM prediction of a particular TF was to be correct, 
we trained a logistic regression model with the R package “stats” [117] using different properties 
associated with the regulatory network architecture and the target genes. Logistic regression is a 
  48
supervised machine-learning model [118] designed to learn the probability that a particular response Y 
belongs to a particular category given the state of input predictor features (X1,…, Xp) based on the 
following relation: 
 
)...exp(1
)...exp(
)...|(
110
110
1
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pp
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

  (5)
In this case, the category we predicted was whether the PROM prediction for a TF overexpression growth 
defect would be ‘TRUE’ or ‘FALSE,’ where ‘TRUE’ indicated either a true positive or a true negative 
prediction, and ‘FALSE’ indicated either a false positive or a false negative prediction. The predictor 
features we used to train the initial model were: for each TF, (1) the number of metabolic target genes, (2) 
the number of target genes that were highly confident essential, (3) the fraction of target genes that were 
highly confident essential, (4) the average number of TFs that regulated the target genes, (5) the number 
of combinatorial regulators interacting with the target genes, (6) the variance of the PROM predicted 
growth ratio across different sampling iterations, and (7) whether the PROM growth defect prediction 
agreed with the iMAT prediction. To refine the logistic regression model, we retrained the model using 
only the features that were evaluated to be significant by the z-statistic [118]. To test the predictive 
performance of the refined logistic regression model, we performed ten-fold cross-validation using the R 
package “cvTools” and calculated the average ROC AUC across the iterations [119].  
Experimental validation of condition-specific growth rates 
We experimentally tested the growth phenotype predictions generated by MTBPROM2.0. We used 
transcription factor overexpressing strains of M. tuberculosis H37Rv generated from previous work [17, 
111, 120]. We cultured the transcription factor overexpressing strains in aerobic conditions in 
Middlebrook 7H9 media [106] with ADC supplement (Difco), 0.05% Tween80 at 37°C with constant 
agitation, as described previously [17, 111, 120]. Growth was measured with optical density of culture 
(OD) at 600nm sampled at 2-day intervals. At an OD600 of approximately 0.1, overexpression of the 
target transcription factor was induced for the approximate duration of one cell doubling (18 hours) using 
an ATc concentration of 100ng/mL, as described previously. Growth rates of the strain overexpressing TF 
were compared to growth rates of the strain without induction. To test metabolite supplementation, we 
grew the strains with and without induction of overexpression in 7H9 supplemented with 2mM of the 
metabolite.  
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RESULTS 
We reconstructed an updated regulatory-metabolic model for MTB using the PROM framework. The 
updated model, MTBPROM2.0, incorporated a knowledge expansion in both the metabolic and 
regulatory components. Table 8 summarizes the updated information incorporated the integrated 
regulatory-metabolic model.  
Transcriptional Regulatory Network Updates 
The transcriptional regulatory network component represented the most substantial expansion of 
knowledge in the integrated model. The MTBPROM1.0 model used a regulatory network constructed in 
2008 based on interactions that were previously documented in the MTB literature, gene pairs that have 
orthologous regulatory interactions in E coli, and operon information [19]. The portion of the network 
that linked transcription factors (TFs) to metabolic genes consisted of 218 interactions between 30 TFs 
(14% of all TFs) and 178 metabolic genes (27% of the metabolic genes in iNJ661, 4% of all MTB genes). 
For the updated model MTBPROM2.0, we constructed a greatly expanded regulatory network based on  
transcription factor binding measured with genome-scale ChIP-seq experiments performed for 206 
transcription factors (96% of all TFs) (described in [18]). We used, for the purposes of integrating with 
the regulatory-metabolic model, the subset of interactions from the ChIP-seq binding network wherein the 
TF binding footprint was located proximally to transcriptional start sites (i.e. region spanning 150 bp 
upstream to 70bp downstream of start site), and included indirect interactions based on operon 
information. We also considered only interactions between the TFs and the genes in the metabolic model 
iSM-MTB-810. The resulting updated regulatory component included 2555 interactions for 104 TFs 
(49%) that linked to 647 metabolic genes (80% of the metabolic genes in iSM-MTB-810, 16% of all 
MTB genes). Importantly, the expanded coverage of regulatory interactions to metabolic genes provided 
by the ChIP-seq-based network facilitated the modeling of a broader set of metabolic consequences to TF 
perturbations. 
Updated regulatory-metabolic model improves prediction of TF gene essentiality 
We integrated the updated regulatory component with the updated metabolic model described in Chapter 
3, iSM-MTB-810, using the PROM framework to generate the updated metabolic-regulatory model, 
MTBPROM2.0. We use the integrated regulatory-metabolic model MTBPROM2.0 to simulate the effect 
of transcription factor knockouts on MTB growth rates. To infer the strength of each regulatory 
interaction for each TF knockout simulation, we calculated the conditional probability that each target 
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metabolic gene was on in the absence of each transcription factor using microarray gene expression data 
(see Methods for details). We used as input a dataset that measured the gene expression profiles resulting 
from overexpressing each of 206 TFs (which include all of the TFs in the regulatory component of our 
model), as described in [111]. This dataset was particularly suited to inferring the strength of each TF-
target gene interaction because it measured the consequences of systematic regulatory perturbations. 
These inferred regulatory influences were mapped onto the metabolic model to simulate the consequent 
growth phenotype (see Methods for details). We simulated TF knockout growth phenotypes across 
multiple media conditions (see Appendix C for visual complete set of simulation results). 
To validate the extent to which MTBPROM2.0 could predict growth effects of transcription factor 
knockouts, we compared the simulated TF knockout predictions with experimentally derived gene 
essentiality data generated by Griffin et al. [107]. Figure 10 shows the predicted growth ratios, relative to 
wild-type, of each TF knockout in the defined medium used to generate the Griffin essentiality data. The 
Griffin essentiality confidence scores are plotted in Figure 10 as blue crosses. The TFs were grouped into 
three categories: those with Griffin essentiality confidence scores less than 0.1 were labeled as highly 
confident essential, those with scores greater than 0.9 were labeled as highly confident non-essential, and 
the remaining TFs with intermediate Griffin essentiality confidence scores were grouped in the third, 
‘intermediate’ category.  
We evaluated the ability of using PROM predicted knockout growth rate ratios to distinguish between TF 
knockout strains that were highly confident essential (Griffin score < 0.1) from TF knockouts that were 
non-essential (Griffin score > 0.9). Figure 2B shows the performance of MTBPROM1.0 and 
MTBPROM2.0 derived growth predictions, as represented by a Receiver Operating Curve (ROC) (see 
Methods for details). MTBPROM2.0 yielded an AUC of 0.68, demonstrating an improved ability to 
correctly identify essential TFs (sensitivity) and non-essential TFs (specificity) over a broad range of 
thresholds compared to MTBPROM1.0, which had an AUC = 0.5. 
Updated model predicts transcription factor overexpression growth defects 
To extend the predictive scope of the PROM framework, we modified the simulation to enable prediction 
of transcription factor overexpression growth phenotypes (see Methods for details). 
As validation, we compared the PROM predicted overexpression growth ratios to experimentally 
measured doubling time ratios of transcription factor overexpression strains with and without the 
induction of overexpression [111]. We used the 60% quantile in the doubling time ratios as a growth 
defect cutoff threshold (corresponding to a overexpressed TF vs. not overexpressed TF doubling time 
  51
ratio of 1.45). Figure 11A shows the experimental overexpressed vs. not overexpressed doubling time 
ratios of the TFs in MTBPROM2.0 (doubling time ratios greater than 5 are shown truncated). The bars 
were color-coded based on whether the MTBPROM2.0 simulation predicted a growth defect upon the 
overexpression of each TF. The predictive performance of using MTBPROM2.0 to distinguish between 
TFs that induced growth defect when overexpressed from those that did not was visualized in the ROC in 
Figure 11B (AUC = 0.69). 
To assess the quality of the MTBPROM2.0 predictive performance, we compared MTBPROM2.0 
performance with the predictive ability of using (1) the number of significantly repressed essential 
metabolic genes (target metabolic genes with Griffin < 0.1), and (2) the condition-specific iMAT models 
described in Chapter 3. We found that the predictive performance depended on the doubling time cutoff 
threshold used to label TFs as growth defective or not growth defective (see Figure 12). MTBPROM2.0 
has the highest predictive performance than using the number of repressed essential genes when the cutoff 
threshold is set at the 60th percentile of doubling ratios (MTBPROM2.0 AUC = 0.69, iMAT AUC = 0.57, 
repressed essential genes AUC = 0.58), and it has lower performance when the cutoff threshold is set at 
the 90th percentile of doubling ratios (MTBPROM2.0 AUC = 0.59, iMAT AUC = 0.72, repressed essential 
genes AUC = 0.78). This suggests that the strength in the predictions in MTBPROM2.0 lies in its 
sensitivity to predict defects in TFs that have mild growth defects. 
Estimating the confidence of PROM TF overexpression phenotype predictions 
To determine whether there existed subsets of TFs that were more likely to yield correct growth 
predictions, we attempted to stratify the TFs based on different properties (see Table 14 in Appendix B 
for complete list). We used these different features to train a logistic regression model to estimate the 
confidence that each TF overexpression growth defect prediction by MTBPROM2.0 would be correct (see 
Methods for details). Of the variables we tested, we found three contributed significantly to the logistic 
regression model: (1) whether the MTBPROM2.0 prediction for a particular TF matched the iMAT 
prediction, (2) the degree of variance in the predicted growth ratio across the different iterations, and (3) 
the average number of TF interactions that regulated each essential target gene.  
We performed ten-fold cross-validation on our logistic regression model to evaluate its ability to predict 
TFs with growth effects correctly simulated by MTBPROM2.0, and found an average cross-validation 
ROC AUC of 0.84±0.11 (see Figure 13). The high performance of the logistic regression model implied 
that the logistic regression model could be used to help prioritize the TFs that should be followed-up in 
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further experiments, and the logistic regression model identified properties of TFs that made their 
phenotypes difficult to predict by MTBPROM2.0. 
The coefficients of the logistic regression model suggested that the probability of correct phenotype 
prediction improved when the MTBPROM2.0 prediction matched the iMAT prediction, that it was 
lowered for TFs with target genes that had many alternate regulators, and that it was improved when the 
growth prediction was consistent across different iterations of sampling. The three factors that 
significantly contributed to the prediction of the likelihood of a true MTBPROM2.0 prediction 
collectively suggested that MTBPROM2.0 predicted more successfully TFs that were not associated with 
complex regulation. The negative association between likelihood of a true MTBPROM2.0 prediction and 
the average number of regulatory interactions influencing the essential target genes indicated that 
MTBPROM2.0 was more likely to predict correctly for TFs linked to metabolic genes that had simple 
regulatory architectures (i.e., those that have few influences from TFs other than the one being perturbed). 
It made sense that the PROM framework would have difficulty predicting the consequence of interactions 
to metabolic genes that involve multiple regulators because the PROM framework was designed to 
account only for the effects of individual TF perturbations, without explicitly factoring in combinatorial 
regulation effects. The positive association between the likelihood that a MTBPROM2.0 prediction was 
true and (1) whether the MTBPROM2.0 prediction matched the iMAT prediction or (2) whether the 
variance in the predicted growth ratios were low, both suggested that the MTBPROM2.0 performance 
depended on whether the influence of a TF upon its targets could be successfully estimated from the gene 
expression data. Increased variance in the MTBPROM2.0 predicted growth ratios across different 
sampling iterations indicated increased variance in the estimations of the conditional probability of TF 
influence, which in turn implied high uncertainty in estimating the true TF influence on target genes. 
Likewise, disagreement between iMAT and MTBPROM2.0 predictions also suggested uncertainty in the 
estimates of the TF influence on its targets. In such cases when it was difficult to estimate the influence of 
the TF on the target genes, there was also less assurance that MTBPROM2.0 estimated TF influences 
sufficiently captured the biological reality. The uncertainty in the estimation of TF influences on its 
targets and might suggest the presence of complex, condition-specific regulatory mechanisms, which 
would confound the assumptions made by the MTBPROM2.0 TF influence estimation approach. These 
three properties suggested that future regulatory-metabolic models may yield the greatest improvement by 
developing approaches that better capture the regulatory influences of TFs associated with complex 
regulation. 
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Condition-specific MTBPROM2.0 simulations predict recovery of growth defect with metabolite 
supplementation 
We used MTBPROM2.0 to predict the effect of TF perturbations in a broad range of media conditions. 
We simulated the growth ratios relative to wild-type of all TFOE perturbations under the different carbon 
and nitrogen sources that correctly yielded nonzero growth rates in iSM-MTB-810, as well as under 
Middlebrook 7H9 conditions supplemented with each of the metabolites that had external exchange 
reactions in the model (Figure 36 in Appendix B for complete list of detailed predictions). We predicted 
several TFs to have different growth phenotypes across different media conditions. 
One such example of a TF with predicted condition-specific growth phenotypes was Rv1404. Rv1404 is 
annotated as a probable transcriptional regulatory protein that contains a DNA-binding domain with some 
similarity to the E coli marR [82, 121]. MTBPROM2.0 predicted a growth defect upon overexpression of 
Rv1404 in 7H9 media conditions and recovery in several alternate media supplementations, including 
with serine as a nitrogen source. Rv1404 was predicted by MTBPROM2.0 to influence two target 
metabolic genes: Rv1731, which is associated with glutamate degradation, and Rv1306, which is a 
component of ATP synthase. Examination of the gene expression profile of Rv1404 overexpression 
revealed that Rv1731 was significantly repressed in the overexpression condition, whereas Rv1306 was 
not significantly differentially expressed. Since the Rv1404 overexpression microarray data suggested 
that the Rv1404 exerted a strong effect on Rv1731, and since glutamate is used as a nitrogen source in 
7H9 media, we tested the effect of serine supplementation as an alternate nitrogen source on MTB growth 
with and without Rv1404 overexpression.  
Figure 14 shows experimental growth curves of uninduced and induced Rv1404 overexpression in MTB 
with and without the presence of serine in the media (see Methods for details of the experimental 
procedure). The red lines show the growth profiles of MTB without induction of Rv1404 overexpression. 
The blue lines are the growth profiles of MTB with induction of Rv1404 overexpression. The dashed 
lines (both red and blue) are the growth profiles of the cultures that contained supplemented serine. The 
growth curves showed that in the absence of serine, the Rv1404 overexpressing culture had a growth 
defect relative to the non-overexpressing culture. However, in the presence of serine supplementation, the 
Rv1404 overexpressing culture had markedly faster growth than the culture without serine, and was at 
least as fast as the non-overexpressing cultures (the presence of serine does not appear to substantially 
affect the growth rate of the non-overexpressing culture). This experimental result represented a 
preliminary validation of a condition-specific growth phenotype predictions made by MTBPROM2.0. 
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DISCUSSION 
In this work, we generated an updated integrated regulatory-metabolic model for MTB. This updated 
model encapsulated expanded and improved knowledge in the metabolic and regulatory systems. The 
updated model could predict the metabolic consequences of TF knockout or overexpression under 
different environmental and genetic perturbation conditions. We furthermore found that the likelihood 
that MTBPROM2.0 would generate a correct phenotype prediction of a given TFOE condition was 
significantly associated factors linked to the complexity of the regulatory network. 
The improvement in gene essentiality predictive performance of observed with MTBPROM2.0 compared 
to MTBPROM1.0 further supports the need for refining and expanding the mechanistic knowledge 
represented by the metabolic and regulatory model components. Moreover, incorporating additional 
regulatory and metabolic reaction information also expanded the scope of the predictions, enabling 
predictions on a greater number of transcription factors than MTBPROM1.0. Therefore, continuing efforts 
to improve the representation of biochemistry and regulation in the metabolic and regulatory model 
components will likely generate more comprehensive predictions that are more reflective of MTB 
behavior. 
Expanding the PROM framework to enable prediction of TF overexpression phenotypes opened a new 
dimension of in silico screening that can be followed up with experiments. Given that the experimental 
tools are already in place to control and monitor the effects of TF overexpression in MTB [17, 111, 120], 
introducing this predictive capability further facilitated the ability to translate PROM predictions into 
tractable experiments. Transcription factor overexpression is also a more physiological perturbation than 
knockout, since most transcription factors will undergo differential expression under exposure to different 
conditions, whereas complete gene knockout would usually result only from genetic mutation. Being able 
to exploit overexpression to perturb MTB phenotype may open therapeutic possibilities for different 
modes of drugs. Leveraging the ability of MTBPROM2.0 to simulate a broader set of genetic 
perturbations under a greater range of conditions, we can begin to gain a better understanding of the 
condition-specific genetic sensitivities of MTB. 
There remain substantial aspects of regulation that are not captured within the scope of the PROM 
framework. In addition to generating growth phenotype predictions on TF overexpression perturbations 
with MTBPROM2.0, we also developed an accompanying logistic regression model that could predict the 
likelihood that MTBPROM2.0 will correctly predict the growth phenotype for a particular TF based on 
the properties of that particular TF. Our logistic regression model can be applied to help stratify the TFs 
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into those that fall into the scope of the PROM predictions, and those TFs that are associated with 
regulation that is more complex than the scope of the PROM framework. By being able to distinguish 
between TFs that are amenable to PROM predictions and those that are not based on the properties of the 
TF regulatory structure, we can target different strategies of regulatory-metabolic modeling to different 
subsets of TFs. 
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FIGURES AND TABLES 
 
Figure 10. MTBPROM2.0 Predicted Knockout Growth Ratios. (A) The predicted growth ratios of each TF 
knockout relative to wild-type are plotted as box plots. The distribution visualized represents the range of the growth 
ratios that result from sampled estimates of the TF-target gene interaction influence. The Griffin essentiality 
confidence scores are plotted as blue crosses. (B) The performance of the MTBPROM2.0 is visualized and compared 
to MTBPROM1.0 in the ROC curves. MTBPROM2.0 (blue) has an AUC of 0.68, and MTBPROM1.0 (red) has an 
AUC of 0.5. 
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Figure 11. Predicting growth defects caused by transcription factor overexpression. (A) Experimental 
overexpressed vs. not overexpressed doubling time ratios of the TFs in MTBPROM2.0 (doubling time ratios greater 
than 5 are shown truncated). The bars are color-coded red if MTBPROM2.0 simulation predicted a growth defect 
upon the overexpression of each TF, and blue if no defect was predicted. (B) ROC curve for the predictive 
performance of MTBPROM2.0. The AUC is 0.69. 
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Figure 12. Comparing TFOE predictive performance of MTBPROM2.0 vs. iMAT vs. using the number of 
significantly repressed essential metabolic genes. The performance is visualized with ROC curves of 
MTBPROM2.0 (blue), iMAT (red), and of using the number of repressed essential metabolic genes (green). (A) The 
doubling time cutoff threshold for growth defect used was set at the 60th percentile, corresponding to a doubling time 
ratio of 1.45. Under this threshold, MTBPROM2.0 achieves an AUC = 0.69, iMAT achieves an AUC = 0.57, and the 
number of significantly repressed essential metabolic genes achieves an AUC = 0.58. (B) The doubling time cutoff 
threshold for growth defect used was set at the 90th percentile, corresponding to a doubling time ratio of 2.6. Under 
this threshold, MTBPROM2.0 achieves an AUC = 0.59, iMAT achieves an AUC = 0.72, and the number of 
significantly repressed essential metabolic genes achieves an AUC = 0.78. 
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Figure 13. ROC curve of performance for logistic regression model, which predicts whether the 
MTBPROM2.0 simulation for a particular TFOE growth phenotype would agree with experiment. The 
logistic regression model correctly predicts TFs that have a correct MTBPROM2.0 simulation with an AUC of 0.86 
when tested on all of the data and an AUC of 0.84±0.11 in cross-validation. 
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Figure 14. Condition-specific growth rates of Rv1404 overexpression. The red lines represent the Rv1404 strain 
without induction of over-expression. The blue lines represent the Rv1404 strain with induction of Rv1404 
overexpression. The dashed lines represent the cultures that were supplemented with serine. The growth curves 
indicate that Rv1404 overexpression leads to a lower growth rate than without overexpression. Moreover, the strain 
with Rv1404 overexpression induced grows markedly faster with the supplementation of serine than when serine is 
absent, with a growth curve that is at least as fast as the uninduced strains.  
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Table 8. Summary of the updated integrated regulatory-metabolic model properties. The model attributes are 
compared between the initial regulatory-metabolic model constructed for MTB described in [23] (MTBPROM1.0) 
and the updated model (MTBPROM2.0). The updated model contains more coverage of metabolism and regulation. 
Feature MTBPROM1.0 model 
MTBPROM2.0 
model 
Metabolic model iNJ661 iSM-MTB-810 
Number of reactions  
(literature based) 1025 (200) 938 (336) 
Number of metabolic genes 661 810 
Regulatory network Balazsi 2008 Minch 2014 
Number of transcription factors 30 104 
Number of genes 783 2825 
Number of interactions 937 6289 
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Table 9. Logistic regression model coefficients of parameters associated with the likelihood that the 
MTBPROM2.0 would correctly predict the overexpression growth phenotype of each TF. The table of 
parameter and their corresponding values is shown in Table 14. The sign of the logistic regression model coefficient 
‘Estimate’ denotes whether the association between a particular parameter is correlated or anti-correlated with the 
likelihood of a correct MTBPROM2.0 prediction. 
Coefficient Estimate Standard Error Z value P(>|z|) 
(Intercept) 0.53194 0.50949 1.044 0.2965 
iMAT agree PROM 2.202 0.57194 3.85 0.0001* 
# Metabolic Targets 0.08812 0.05884 1.498 0.1343 
# Essential Metabolic Targets -0.34244 0.23538 -1.455 0.1457 
Fraction Essential Targets 0.15536 0.97412 0.159 0.8733 
Average # TFs for Essential Targets -0.38698 0.18146 -2.133 0.0330* 
# Combinatorial TFs for Essential Targets 0.13331 0.25429 0.524 0.6001 
PROM growth STD -223.52621 113.80372 -1.964 0.0495* 
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CHAPTER 5: Conclusions and Future Directions	
Systems biology modeling approaches are designed to make sense of complex processes like those 
underlying lung diseases. The work described in this thesis involved contributions to two different 
modeling strategies to tackle lung disease from the perspective of the human host system and the disease-
causing bacterial system. The data-driven statistical models that were the basis for the lung disease 
classification approaches studied in Chapter 2 made predictions based on patterns learned from human 
sample input data without explicit regard for underlying mechanism. In contrast, the mechanistic 
metabolic and regulatory-metabolic models of the disease-causing pathogen constructed in Chapter 3 and 
Chapter 4 were constructed specifically to recapitulate our understanding of regulatory and metabolic 
processes. 
Challenge of robust molecular disease diagnostics  
Molecular disease diagnostics have the potential to yield noninvasive tests that can screen the population 
at large and can accurately detect diseases before symptoms arise. A major obstacle in the search for 
clinically translatable molecular disease diagnostics is the difficulty of finding robust classifiers because 
of substantial study-specific variability in gene expression. My work has shown that combining data 
gathered from multiple independent sites in a collective analysis can mitigate the impact of such study-
effects on consequent disease classification. By comparing the performance results from randomized 
cross-validation and inter-study validation, we can determine the extent to which study-effects are still 
confounding classification outcomes, implying that introducing additional datasets would be beneficial. 
Our finding that, after an incorporating a degree of heterogeneity representative of inter-study variability, 
including data from additional independent studies does not further improve classification performance. 
These findings have multiple implications for the design of future molecular diagnostic finding efforts.  
First, my work has underscored the importance of including data collected from multiple experimental 
sites to train biomarker-learning methods in order to adequately capture a representative sampling of 
heterogeneity in the phenotypes being considered. Importantly, future work searching for robust 
biomarkers would benefit from assembling, processing, and analyzing data from multiple data collection 
sites, preferably sampling different segments of the population, in both the classifier learning step and the 
validation step. 
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One must be careful in the cross-study integration process to avoid introducing additional heterogeneity, 
however. For example, in microarray data, there exist many different preprocessing algorithms that 
normalize and summarize the raw probe intensity readouts into expression values in different ways. We 
found that combining data from studies that used different preprocessing methods introduced a significant 
new dimension of variance in the gene expression values that confounded classifiers and reduced 
classification performance. Therefore, in future integrative analyses, applying a consistent preprocessing 
algorithm on all of the data prior to subsequent analysis is the best strategy to resolve this issue; however, 
probes that target a particular gene may not completely overlap on different microarray platforms, which 
would interfere with consistent preprocessing efforts (consistent preprocessing should always be possible 
with raw RNA-seq data since there are no probe-based limitations). When consistent preprocessing is not 
possible, including all preprocessing methods in all of the phenotypes being compared will at least reduce 
the degree to which the difference in preprocessing method will dominate any inter-phenotype variance in 
the expression data. Similar practices could also be applied to control for other technical factors that can 
be standardized. 
Second, my approach to quantifying the impact of study-effects on classification with comparative cross-
validation analysis can be used to determine which phenotypes would benefit most from further data 
gathering. Since the degree of heterogeneity required to adequately represent a phenotype in classification 
is dependent on the phenotype, some phenotypes will require data from a greater number of independent 
sources than others. Furthermore, our classification results showed that even when impact of study-effects 
on classification was mitigated by sufficient inclusion of study data, prediction error was in some cases 
still significant (in excess of 20% prediction error). This indicated that heterogeneity inherent to the 
phenotype may still be affecting predictive performance and implied that shifts in classification strategy, 
such as further stratification of the phenotype, consideration of a different measurement type, or 
integration of network information, may be necessary to further improve classification. Analyzing 
classification prediction with comparative cross-validation analysis can help inform which phenotypes 
would most benefit from additional data gathering, and which phenotypes would require a different 
approach to improving classification prediction. 
One such strategy has been to offset variability applying transformations to the data. While these efforts 
have been shown to make substantial progress in mitigating technical batch-effects, one must be judicious 
in applying these transformations. My analysis showed that non-phenotype-specific heterogeneity in gene 
expression data is not linear in all features; thus, applying global transformations may be insufficient to 
mitigate the associated prediction error. Moreover, it is often difficult to tease apart heterogeneity that is 
associated with the phenotype from the variability that is not related to the phenotype. Therefore, it is 
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possible that some data transformations will obscure a component of the phenotype-specific signal in the 
course of correcting for variability associated with non-phenotype-specific factors. Combining 
transformation methods that take into account metadata describing experimental conditions and potential 
sources of variability with other strategies, including integration of multiple types of measurements and 
contextualization with network information, may be the optimal path forward. 
Challenge of predictive mechanistic modeling of biological systems 
The promise of models that leverage knowledge of the underlying biological circuitry to generate 
mechanistic predictions of phenotypes is appealing in both the models’ potential ability to succinctly 
summarize our understanding of the underlying processes associated with observed behaviors and in the 
models’ potential utility in predicting multiple alternative intervention strategies to adjust the outcome to 
a desired phenotype. The challenge of such mechanistic modeling arises from the limits in the collective 
knowledge of the systems being modeled. Large gaps lie in the knowledge of even well characterized 
systems, such as metabolism, in well-studied model organisms, such as Escherichia coli. Moreover, 
models further simplify this knowledge in order to be computable, introducing assumptions and 
generalizations that may impact the prediction outcomes. For example, most mechanistic models have 
separated metabolic disjoint approaches. However, there is substantial cross-talk and feedback across 
these three different biological processes which substantially influence phenotypic outcomes. Even with 
multiple efforts, including mine, to develop and refine regulatory-metabolic models that simulate the 
metabolic effects of transcription factor perturbations, the field is still far from accounting for the 
complexity of the regulatory and metabolic influences. Ultimately, these mechanistic models are 
‘descriptions of our pathetic thinking’ of the underlying biology [122]; the key to their relevance is the 
extent to which we can extract useful predictions from such incomplete representations. That efforts using 
mechanistic models to drive predictions have had some success suggests that we can recover predictive 
insight for some phenotypes even without complete knowledge of the system. Determining which 
phenotypes can be modeled with by rough representations of mechanism and which phenotypes require 
more detailed, in-depth models can shed light into the complexity of the phenotypes themselves. 
My work has shown that we can predict with significant accuracy phenotypes of transcription factor 
phenotypes with a mechanistic regulatory-metabolic model of MTB, and that we can improve predictive 
ability by integrating more biochemical knowledge into mechanistic models. Even though our model 
makes many assumptions and simplifications, a significant proportion of predictions generated can be 
successfully validated. Therefore using mechanistic models to screen and generate hypotheses for 
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interesting targets can help to prioritize experiments that further extend knowledge of the underlying 
biology.  
In addition to generating phenotype predictions with significant accuracy using my mechanistic 
regulatory-metabolic model, I was also able to develop a classifier that could distinguish between TFs that 
were likely to be predicted correctly, and TFs that were not likely to be predicted correctly. Being able to 
stratify TFs into those that are likely to be predicted correctly and those that are unlikely to be predicted 
correctly based on properties associated with the TFs and its regulatory targets serves two advantages. 
First, this gives a different criterion with which to rank predictions are most promising to follow-up in 
experiments. Although in silico predictions are easy to make in high throughput, it is often difficult to 
follow-up on more than a handful of predictions with in-depth experimental characterization. Therefore, 
having means to prioritize the predictions that are most likely to yield meaningful follow-up results will 
streamline the iterative process of investigation. Second, the ability to identify properties that make a TF 
hard to predict by the current regulatory-metabolic model also can help method development for 
improvements that can address the current limitations. The features that can successfully predict whether 
a particular mechanistic model prediction is likely to be correct depend on the specific context of the 
prediction problem. In the case of using MTBPROM2.0 to predict TF overexpression growth phenotypes, 
the factors used to stratify the TFs suggest that being able to account for more complex regulatory 
mechanisms would benefit predictive ability. Future method development to address combinatorial 
regulation and the effects of both activation and repression may help to improve overall predictive 
accuracy for regulatory-metabolic models.  
Outlook 
The work described in this thesis involved statistical and mechanistic modeling strategies from the 
perspective of the human host and the disease-causing pathogen system. Examining lung disease from the 
human and the pathogen system afforded context-dependent advantages and disadvantages. We chose to 
address multi-disease diagnosis from the human perspective to reduce the search space of potential 
biomarkers—perturbations will be observed in the human patient irrespective of whether or not the 
disease was caused by some external, potentially unknown pathogen. In contrast, searching for potential 
drug targets from the pathogen side offers the dual advantage of facilitating a focused, pathogen-specific 
gene search (helping to reduce off-target effects), and of modeling a microbial system, which has much 
less complexity to account for in mechanistic models than human systems. Applying diverse modeling 
approaches and systems of study enables a multi-pronged approach to tackling complex problems.  
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The statistical and mechanistic models used in this thesis work have several complementary properties. 
Mechanistic models are easily interpreted and function based on the interconnection of multiple causal 
relationships. Despite this, mechanistic models are severely knowledge-limited for most biological 
systems because mechanistic characterization of individual components requires extensive experimental 
effort. The incomplete knowledge of underlying mechanism limits the scope of mechanistic model 
predictions. Statistical models, on the other hand, do not depend on knowledge of underlying mechanism, 
so these models can yield high predictive performance even for complex phenotypes where the etiologies 
are completely unknown. Additionally, some of the patterns extracted from the data by statistical models 
can inform the discovery of new mechanistic associations. However, statistical models are learned from 
data that are sensitive to many different sources of variability unrelated to the phenotype being probed, 
and the models extract predictive associations that are often difficult to interpret. Contributions in the 
field, including the work described in this thesis, have made improvements to generation and application 
of statistical and mechanistic models. Nevertheless, given the complementary properties of statistical and 
mechanistic models, additional predictive utility may be gained from improved integration of statistical 
and mechanistic models such as by using hybrid statistical-mechanistic models. 
Collectively, computational models are immensely useful tools that aid the investigation of complex 
problems, including the development of improved diagnostics and therapeutics for lung diseases. With the 
ever-growing influx of high-throughput measurements and the continued accumulation of literature that 
span back decades, modeling approaches are harnessed to contextualize this data and extract useful 
insight. Models in turn generate predictions of phenotypes that reflect our assumptions of how the 
biological systems should be working, which can be tested in subsequent targeted experiments. In this 
way, synergizing iterations of modeling and experiments can focus and streamline the acquisition of new 
understanding in complex systems. 
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APPENDIX A: Supplementary Information for Chapter 2 
 
Technical batch-effects can arise from differences in microarray 
preprocessing 
A significant source of technical batch-effects comes from the data preprocessing required to yield gene 
expression values from microarrays. The raw Affymetrix oligonucleotide microarray measurements 
require in silico preprocessing to reconcile them into expression values. Several different preprocessing 
methods have been developed to perform this analysis; the three methods used by the studies included in 
our meta-analysis were MAS5 [123], RMA [124], and GCRMA [62].  
We studied the effect of including data processed with different procedures on binary TSP and SVM 
classification performance on a small test subset of the meta-analysis data. The subset incorporated data 
from ADC (77 samples from GSE10245, GSE17475, and GSE10799) and SCC (75 samples from 
GSE10245, GSE2109, and GSE6253). The raw intensity files were compiled and each sample was 
preprocessed with both RMA and GCRMA using MATLAB. We assembled datasets composed of 
different mixtures of preprocessing methods (i.e.: 0%, 25%, 50%, 75%, 100% RMA, remainder 
GCRMA) and compared the classification accuracies achieved. For each input dataset containing both 
RMA and GCRMA preprocessed data, we tested 20 dataset splicing permutations that preserved the 
RMA/GCRMA ratio.  
We found that binary classification accuracy was significantly reduced when we included datasets 
generated by heterogeneous preprocessing methods (p < 0.05 Wilcoxon ranksum test) (see Figure 15A). 
We further found that the TSP algorithm tended to select the same classifiers consistently across different 
rounds of randomized cross validation when consistent preprocessing had been applied to all samples, 
whereas the algorithm tended to select disjoint classifiers during different rounds of cross validation when 
a mix of the preprocessing schemes were applied to the samples (see Figure 15B).  
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Figure 15. Performance of binary TSP and SVM classification at different RMA/GCRMA preprocessing 
ratios. (A) Accuracy of classifying between ADC and SCC. The x-axis indicates the percent of data included in 
training that were processed by RMA. The remaining fraction of the data were processed by GCRMA (1-%RMA 
samples). The error bars represent standard deviation from 20 permutations. (B) Consistency of TSP classifiers 
selected among different iterations of cross-validation for different fractions of samples with RMA processing. The 
x-axis show the gene ID number, and the y-axis indicates the frequency that a particular gene was selected as a TSP 
classifier in an iteration of cross-validation.  
Datasets with mixed RMA/GCRMA processed samples showed that different genes were selected as 
classifiers in different iterations of cross-validation. In contrast, datasets with only RMA or only GCRMA 
processing yielded classifiers that were repeatedly selected across different iterations of cross-validation. 
This suggested that RMA and GCRMA transformed the data in disparate, nonlinear ways, so that mixing 
preprocessing procedures introduced a source of non-phenotype associated variability. To mitigate the 
variability introduced to the data by mixed preprocessing, we preprocessed the raw .CEL files of all of 
our samples in a consensus set with the approach described below, and we used this consensus-
preprocessed dataset for all of the classification analyses described in Chapter 3. 
Mitigating batch-effect with consensus preprocessing 
The Affymetrix oligonucleotide microarrays measure gene expression by quantifying intensity of 
fluorescently labeled gene fragments that bind to sets of 25-mer oligonucleotide probes on the chip with 
specific sequences tailored to be complementary to the target genes. In addition to ‘perfect match’ probes 
that are perfectly complementary to regions of a target mRNA, Affymetrix microarrays also have 
A  B
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‘mismatch’ probes, which contain a mismatched nucleotide halfway along the probe sequence (position 
13). These mismatch probes attempt to estimate non-specific binding for the probes corresponding to each 
mRNA gene sequence. Each gene is generally associated with a ‘probe set’ consisting of several pairs 
(usually 11) of perfect match and mismatch probes. The raw measurements for each probe set consist of a 
set of intensities from the probes, which require in silico preprocessing by (1) correcting for background 
variability, (2) normalizing intensities across samples, (3) and summarizing intensities across the probe 
set into a single expression value. The output of the summarization step corresponds to the background 
adjusted expression value for the mRNA of interest.   
We preprocessed using the MATLAB implementation of GCRMA, which corrects for background 
variability by accounting for optical noise, probe affinity, and ‘mismatch’ probe adjustment; normalizes 
intensities by quantile normalization; and summarizes intensities using a median polish method [62]. To 
minimize preprocessing batch effects, it was desirable to preprocess all samples in the entire dataset 
together. Unfortunately, preprocessing requires microarray platform-specific chip specifications 
indicating the locations of each probe on the chip, precluding global preprocessing on meta-analyses that 
use multiple platforms. To address this problem, we developed software to combine the raw CEL data 
files from multiple platforms that share the same probe sets. Importantly, probe sets across the platforms 
we considered contained the same probe sequences. These “consensus datasets” were then preprocessed 
normally using GCRMA. The output of this consensus preprocessing contained only the 22,277 probes 
that existed on both microarray platforms that we use; probes that only appear on one of the platforms 
were excluded from preprocessing and subsequent consideration.  
MAS5call filtering  
The Affymetrix oligonucleotide microarrays standard data preprocessing software, MAS5, includes a 
function that assesses the expression value of each gene as ‘present,’ ‘marginal’ or ‘absent’ based on 
whether or not the measured expression of the ‘perfect match’ probes are significantly greater than the 
‘mismatch’ probes based on the nonparametric Wilcoxon signed rank test [125]. The ‘present’ call is 
made when the p-value of difference is less than 0.04, the ‘marginal’ call is made when the p-value of the 
difference is between 0.04 and 0.06, and the ‘absent’ call is made when the p-value of the difference is 
greater than 0.06, representing no significant difference between the measurements of the ‘perfect match’ 
and the ‘mismatch’ probes. These expression quality calls are used as a basis for filtering probes to be 
considered in the classification scheme.  
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We investigated the classification performance effect of excluding expression probes based on varying 
the threshold of ‘absent’ calls present in the samples. Although the number of genes excluded changed 
substantially depending on the fractional threshold of ‘absent’ calls that we deemed acceptable for a gene 
to be considered in subsequent classification (ranges from 5818 probes with ‘0% absent’ threshold to 
21647 probes with ‘not all samples absent’ threshold), the performance of the TSP tree classification 
scheme did not significantly change as a function of the ‘absent’ call threshold. We choose to use a 90% 
absent exclusion threshold; i.e., genes were excluded from consideration if more than 90% of the samples 
were labeled as ‘absent.’ We performed the MAS5call filtering within the validation loop, excluding 
genes based on the calls of the training data during each iteration of the validation. 
Study effects were observed in RNA-seq data 
Recent advances in sequencing technologies has enabled the use of RNA-seq to measure gene expression 
[70]. Although RNA-seq offers several advantages over microarrays [70, 71], study-specific variability 
has been shown to exist in RNA-seq data [45]. We wished to examine whether these study-effects have an 
impact on phenotype classification performance. 
As a test case, we examined RNA-seq data collected from two independent studies that collected both 
ADC and NORM: GSE37764 [72] and ERP001058 [73], as well as with ADC data from the Cancer 
Genome Atlas (TCGA) [1] and NORM data from dbGaP [74]. We downloaded raw .fastq files from the 
Sequence Read Archive [63] or CGHUB and extracted gene expression counts using STAR alignment 
[64] and HTSeq software (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html).  
We first examined the data from the studies that gathered data from both ADC and NORM. Pairwise 
correlation analysis from the GSE37764 and ERP001058 datasets showed that the Pearson correlation 
coefficients for samples of different phenotypes within a study (average correlation: 0.96) were slightly 
but significantly higher than the coefficients for samples of the same phenotype from different studies 
(average correlation 0.95) (p < 0.05). Moreover, when we performed ten iterations of binary classification 
under ten-fold randomized cross validation (RCV) to distinguish either between phenotype or between 
studies, we found that classification sensitivity and specificity were significantly higher for predicting 
study labels than phenotype labels when SVM was used as the classification algorithm (p < 0.05, 
Wilcoxon ranksum test see Table 10).  
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Table 10. Confusion matrices showing classification performance on RNA-seq data based on study labels or 
phenotype labels. 
SVM Predicted Study Labels Predicted Phenotype Labels 
ERP001058 GSE37764 ADC NORM 
Actual 
Study 
Labels 
ERP001058 0.994±0.02 0.006±0.02 
Actual 
Phenotype 
Labels 
ADC 0.95±0.07 0.05±0.07 
GSE37764 0±0.07 0.9933±0.07 NORM 0.06±0.09 0.94±0.09 
 
We then integrated the data from GSE37764 and ERP001058 with ADC data from the TCGA and 
NORM data from dbGaP to test the extent to which classifiers trained from a single study could correctly 
predict samples collected from other studies. Figure 16 summarizes the sensitivities of classifying ADC 
(blue bars) and NORM samples (yellow bars) after training SVM classifiers on data only from 
ERP001058, from GSE37764, or from TCGA and dbGaP (we used TCGA and dbGaP together to train a 
set of SVM classifiers because each study had only one phenotype). The bars associated with the “CV” 
categories report the ten-fold RCV sensitivities yielded by testing on samples from the same study as the 
training study. The grouped bars in the middle and right of each plot represent the independent validation 
sensitivities from validating on studies not used to train the classifiers. While ADC sensitivity remained 
high during both randomized cross-validation and validation on independent studies, NORM sensitivity 
was appreciably lower in validation on independent studies. Collectively, these results suggested that 
study-effects in RNA-seq data had an impact on phenotype classification. 
Figure 16. Classification sensitivities yielded from training on one study. CV (left-most grouping of bars in each 
plot) indicates cross-validation sensitivities for ADC (blue bars) and NORM (yellow bars). The other groups 
indicate the sensitivities yielded from testing on the indicated study or studies. TCGA and dbGaP data were used 
together to train and test. 
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Extended comparative cross-validation analysis (CCVA) results 
 
Figure 17. Expanded inter-study validation results. These plots are the same as the graphs featured in Figure 1, 
with the added Study ID labels (e.g., the bar on the farthest left in (A) shows that 74% of ADC samples in Study B 
are correctly classified by SVM when Study B is excluded from training). Some Study ID labels appear more than 
once (e.g. Study H matches both a blue ADC bar and a red SCC bar) because those studies have data from multiple 
phenotypes, which have sensitivities that are reported separately. The order of studies in the horizontal axis is 
identical for the two panels. 
Correlation between inter-study validation, randomized cross-validation, and 
sample size  
Figure 18 represents the inter-study validation performance shown in Figure 1 of the main text as a function 
of the sample sizes of the studies being excluded in each iteration of validation. Figure 19 represents the 
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cumulative comparative cross-validation analysis (CCVA) performance shown in Figure 2 of the main 
text as a function of the training set sizes in each iteration of validation.  
 
 
 
Figure 18. Inter-study validation phenotype-specific sensitivity as a function of study sample size. The points 
are color-coded according to the phenotype. 
 
 
Figure 19. Cumulative comparative cross-validation analysis phenotype-specific sensitivity as a function of 
training sample size. The points are color-coded according to the phenotype. 
We tested whether the trends observed in comparing inter-study validation (ISV) with 
randomized cross-validation (RCV) could be correlated with sample size of the associated study or 
phenotype. Figure 20 shows the plot of ISV sensitivity for each study as a function of the study sample 
size and the plot of RCV sensitivity for each phenotype as a function of the phenotype sensitivity. 
Correlation analysis revealed that neither ISV nor RCV performance correlated significantly with sample 
size (Spearman correlation coefficient = 0.2 for ISV vs. study sample size; Spearman correlation 
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coefficient = 0.1 for RCV vs. phenotype sample size; p > 0.05 for both). This suggested that the 
comparative cross-validation results are primarily associated with factors other than sample size.  
   
Figure 20. Correlation between ISV, RCV and sample number. 
Correlation analysis also showed no significant correlation phenotype-averaged ISV sensitivity 
and RCV sensitivity (see Figure 21, Spearman correlation coefficient = -0.2, p > 0.05). Taking RCV to be 
a metric of the difficulty of the classification problem, the lack of significant correlation to ISV implied 
that ISV performance was primarily associated with factors other than the difficulty of the classification 
problem. 
 
Figure 21. Correlation between average ISV sensitivity and RCV sensitivity. 
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Extended cumulative comparative cross-validation analysis results 
Figures 22-27 show the extended results of CCVA as a function of the number of studies included 
in analysis. The figures include analogous results to Figure 2 A-C in the main text that were generated 
using SVM and ISSAC as the classification algorithm.  
Varying numbers of ADC studies 
 
 
Figure 22. Inter-study validation results varying ADC studies calculated by SVM.  
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Figure 23. Inter-study validation results varying ADC studies calculated by ISSAC. 
Varying numbers of SCC studies 
 
 
Figure 24. Inter-study validation results varying SCC studies calculated by SVM. 
 
Figure 25. Inter-study validation results varying SCC studies calculated by ISSAC.  
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Varying numbers of NORM studies 
 
 
Figure 26. Inter-study validation results varying NORM studies calculated by SVM.  
 
 
Figure 27. Inter-study validation results varying NORM studies calculated by ISSAC.  
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Extended principal component analysis results 
We identified the principal components that separated most effectively by phenotype. We found that the 
3rd, 4th, and 5th, principal components captured more phenotype-associated expression variance than the 1st 
or 2nd principal components, which were largely affected by other sources of variance. In addition to 
examining by visual inspection (see Figure 28), we assessed the extent to which samples of the same 
phenotype were grouped together by measuring the overlap of the phenotype groups with clusters selected 
using k-means clustering. We performed k-means clustering of the gene expression samples transformed 
into different pairs of principal component axes, setting k=6 (number of phenotypes in the analysis). For 
each phenotype, we found the fraction of samples that were labeled as cluster ki for each of the six 
clusters. We calculated this overlap for all of the phenotype-cluster combinations, and reported the 
overlap accuracy of the phenotype-cluster mapping that maximizes the overlap averaged across 
phenotypes.  
 
 
Figure 28. Principal component analysis for the gene expression data examined in our study. (A-C) Colors 
represent phenotype labels. (D-F) Colors represent study labels. 
We found that when the data are represented by the 3rd 4th or 5th principal components, the k-
means clustering overlap is significantly greater than that when the data were represented by the other 
principal components (p < 0.05, t-test, see Figure 29). The k-means overlap accuracy with phenotype 
clusters was 0.37 when data were projected onto the 1st and 2nd principal components. In contrast, the k-
means overlap was 0.57 when data were onto the 3rd and 5th principal components and was 0.61 when 
projected onto the 4th and 5th principal components.  
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Figure 29. K-means clustering overlap with phenotype labels as a function of principal component projection. 
The colored squares represent the accuracy of overlap when the expression data are projected onto the two principal 
components represented by the x and y axes. The average overlap of k-means clusters and phenotype labels for data 
projected to 3rd and 4th, 3rd and 5th, or 4th and 5th principal components is 0.57; the average overlap for data not 
projected to these components is 0.43 (p < 0.05). 
Leveraging the insight gained from PCA over all data considered in our study, we then compared 
the principal component representations of the data with different numbers of studies included for 
analysis (see Figure 30, Figure 31, and Figure 32). As we varied the numbers of considered experimental 
studies in a given phenotype (e.g., ADC), we compared the accuracy of overlap of the samples grouped 
by k-means clusters with the ADC samples in the PCA dataset, as quantified by the average of the 
fraction of ADC samples that were labeled as cluster k* and the fraction of non-ADC samples that are not 
labeled as cluster k*, where k* is the cluster that maximizes this overlap. We calculated this overlap for 
each of the phenotypes with which varied the number of studies included for analysis (i.e., ADC, SCC, 
and NORM).  
We found that when the data are represented by the 1st and 2nd principal component axes, the k-
means clustering overlap was negatively correlated with the increasing the number of ADC, SCC, and 
NORM studies included in the PCA dataset (Pearson correlation coefficient = -0.77, -0.78, and -0.77, 
respectively). In contrast, there was a positive correlation between the k-means clustering overlap and 
increasing the number of ADC and NORM studies when the 3rd and 5th principal component axes 
represent the data (correlation coefficient = 0.54 and 0.32, respectively) and a positive correlation with 
SCC when the 4th and 5th principal components are represented (correlation coefficient = 0.64). For each 
phenotype, when only two studies were included in the analysis, the samples belonging to that phenotype 
appeared in close proximity with other phenotypes. As the number of studies incorporated into the 
analysis increases, the data appeared to progressively shift toward a more separate, phenotype-specific 
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cluster. These results suggested that including the number of studies in a meta-analysis strengthens the 
phenotype-associated signal in the gene expression. 
To substantiate the implications of the k-means clustering overlap, we also assessed the degree to 
which phenotypes were separable as the number of studies for a phenotype increased by examining the 
centroid separation distance. We calculated the Euclidean distance between the centroid of the samples 
belonging to the phenotype and the centroid of the samples not belonging to the phenotype as we varied 
the number of studies of the phenotype included in the analysis. We find that the first two principal 
components yielded a negative correlation between the distance separating phenotype and not-phenotype 
centroids and the number of phenotypes studies included, when the phenotypes ADC, SCC, and NORM 
were considered. However, there was a significant positive correlation between the centroid distance 
separation and the number of studies included (p < 0.05 for each). 
 
 
Figure 30. Principal component analysis with varying numbers of ADC studies (blue). 
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Figure 31. Principal component analysis with varying numbers of SCC studies (red). 
 
 
 
Figure 32. Principal component analysis with varying numbers of NORM studies (yellow). 
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Impact of study-effects on the consistency of gene classifiers 
We examined the feature genes selected via F-score for SVM and the ISSAC gene marker panels for the 
different iterations of cumulative CCVA. As we varied the number of ADC, SCC, or NORM studies 
included in the analysis, we observed some association in the consistency of the ISSAC gene marker 
panels and the F-score feature genes. We found that the number of ADC, SCC, or NORM studies 
included in CCVA was significantly correlated with the number of validation iterations in which the most 
consistent of the ISSAC marker panel genes appeared (Spearman’s rho > 0.61, p < 0.05). There was also 
a moderate but not significant correlation between the numbers of ADC, SCC, or NORM studies included 
in CCVA and the number of validation iterations in which the most consistent of the F-score feature 
genes appeared (Spearman’s rho ranged from 0.25 to 0.81 for the different phenotypes). This suggests 
that by introducing additional study-associated heterogeneity to mitigate the influence of study-effects on 
prediction error, we may also gain some benefit in improving classifier consistency. 
Description of disease classification algorithms used 
Support Vector Machines 
The support vector machines method has been shown to classify phenotypes based on gene expression 
cases with high performance, and has also been amenable to classification in the context of feature 
selection methods [65, 66, 126]. The multiclass one-vs.one support vector machines (SVM) approach 
involves finding a series of maximum separating hyperplanes between samples from each pair of 
phenotypes, as defined by the multidimensional space defined by the expression of an input set of gf  
feature genes [65]. During prediction, each sample is tested against all of the classifying hyperplanes. The 
classification decision for each hyperplane is based on which side of the classifying hyperplane a 
sample’s expression profile falls [65]. The classifications from each of these hyperplanes are combined, 
and the overall prediction was the phenotype picked most frequently among the set of classifiers. We 
trained the multiclass SVM using the LIBSVM library for MATLAB [67]. 
To control the number of input genes considered by SVM to construct each hyperplane, we further 
implemented a feature selection algorithm, based on the F-score metric [66]. The F-score was calculated 
for each gene i as [66, 127]: 
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where j  represented the samples included in the analysis, and l  represented the phenotypes to be 
classified. The ijx  x୧୨represented the expression of the ith gene in the j th sample, and the jy  represented 
the phenotype class of the jth sample. The terms ilx  and ix  represented the mean expression level for a 
gene within a phenotype and across all phenotypes, respectively. The )( ly j   represented the 
Kronecker delta function: 
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We performed feature selection based on the training data within each iteration of validation. To test the 
effect of the number of feature genes used in SVM on ISV and RCV performance, we compared the 
CCVA and cumulative CCVA results of SVM using the top gf = 50, 500, and 5000 genes sorted by the 
F-score and found that the outcomes remained qualitatively comparable across these three selections for 
feature number (see Figure 33 and Figure 34). For convenience, we used the top gf = 50 genes for the 
remaining analyses presented in the main text and supplemental information. 
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Figure 33. Inter-study validation and randomized cross-validation performance calculated for SVM using 50, 
500, or 5000 feature genes. These plots are analogous to Figure 1a in the main text. 
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Figure 34. Cumulative CCVA results for ADC calculated by SVM with 50, 500, or 5000 feature genes. These 
plots are analogous to Figure 2a in the main text. 
Identification of Structured Signatures And Classifiers 
The Identification of Structured Signatures And Classifiers (ISSAC) method [33] is a multiclass 
classification extension of the TSP learning algorithm [50], which predicts phenotypes based on the 
ranked expression levels of samples. To accommodate multiclass classification problems, ISSAC 
constructs a classification tree with an agglomerative hierarchical clustering approach, using the TSP 
score as the distance metric.  
The classification tree informs two methods of sequential TSP comparisons. The first, node-based method 
focuses on the phenotype groups that comprise the nodes of each tree. A modified k-TSP method [128] is 
applied, yielding panels of gene pair classifiers to assess whether or not test samples belong to the 
phenotypes that are grouped at each node. If a sample is affirmatively classified, then it passes through 
both branches spanning from the node and faces classification at both downstream nodes until it reaches 
nodes with only one phenotype. If a sample is not classified as belonging to one of the phenotypes at a 
node, then it is rejected from further classification at downstream nodes. This node-based classification 
can make multiple predictions because a sample might pass classification at multiple branches in the tree. 
Furthermore, rejection of a sample from being classified by the tree indicates that the sample does not 
appear to resemble any of the phenotypes in the tree. 
To break ties resulting from the node-based classification, a branch-based method is leveraged. The 
branch-based classification compares groups on each left branch against groups on the corresponding 
right branch with the binary TSP classification approach, yielding one gene pair classifier per branch. If a 
sample is classified as belonging to a phenotype in the left branch node, then it would subsequently be 
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passed only down the branches that are downstream of the left node. Otherwise, the sample would be 
passed down for subsequent classification at the branches downstream of the right node, akin to a 
decision tree with the binary TSP scheme as the decision metric.  
Training set selection in validation 
The number of microarray samples that belonged to the six lung phenotypes varied substantially, ranging 
from 49 LCLC samples to 580 ADC samples. To mitigate biased classifiers resulting from skewed 
training sample sizes, we implemented for the microarray evaluation a training data subset selection step 
within each iteration of validation. For each iteration of validation, we compared the samples sizes of 
each of the phenotypes represented in the portion of the data not excluded for testing purposes. The 
number of samples of the phenotype with the fewest samples, nlow, was used as a benchmark. Phenotypes 
with sample numbers at least two times nlow were evenly partitioned into disjoint random subsets of size 
comparable to nlow. These partitions were then randomly selected to be included in data used to train the 
classifier. To ensure that classifier selection was not biased by the selection of the partitions, the training 
of the classifier was performed 10 times with independent selections of training data subset for each 
iteration of test set. Therefore, the performance of 10-fold randomized cross-validation with this training 
set selection was averaged from classifiers learned from 100 independent training subsets that were tested 
on 10 different test sets. 
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Table 11: Description of the experimental studies from which the data included in the meta-analysis were derived. 
The ‘Study Label’ column designates the GEO or ArrayExpress study identification numbers. The ‘GPL’ column 
designates the microarray platform used to take the expression measurement, as labeled by GEO (GPL570 
represents HG-U133 Plus 2, and GPL96 represents HG-U133A). The bolded, boxed numbers in the ‘Samples’ 
column report the total number of samples for each phenotype. 
 
Phenotype Study ID 
Study 
Label GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Original Pre-
processing 
Method 
Asthma (AST) 
N GSE18965 96 9 [129] 
airway 
epithelial 
brushing 
Qiagen RNeasy 
Kit 
15ug cRNA, 
16 hr, 45C, 
Affymetrix 
Fluidics 
Station 450 
GCRMA 
(Bioconductor) 
S GSE4302 570 55 [130] 
airway 
epithelial 
brushing 
NuGen Ovation 
RNA 
amplification 
2.75ug cRNA, 
16 hr, 45C, 
Affymetrix 
Fluidics 
Station 450 
RMA 
  
(Bioconductor) 
W GSE7368 570 6 
Goleva 
broncho-
alveolar 
lavage 
cells 
phenol chloroform 
isoamyl alcohol 
extraction Expression 
Analysis 
Technical 
Manual of 
Affymetrix. 
MAS5.0 
   no paper 
ethanol pre-
cipitation 
recovery, 
   Qiagen RNeasy Kit purification 
           70               
Chronic 
Obstructive 
Pulmonary 
Disease (COPD) K GSE1650 96 18 [131] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
8-10ug cRNA, 
overnight, 
Agilent 
confocal laser 
scanning 
RMA 
Superscript II 
reverse trans-
criptase, oligo dT 
primer, T7 RNA 
pol promoter, 
ENZO Bioarray 
RNA transcript 
labeling kit, 
  
Qiagen RNeasy 
Kit purification 
U GSE5058 570 14 [132, 133] 
airway 
epithelial 
brushing 
trizol extraction, 
15ug cRNA, 
16 hr, 45C, 
Affymetrix 
Fluidics 
Station 450 
RMA 
Qiagen RNeasy 
Kit purification 
   Expression Analysis 
Technical Manual 
  
Y GSE8545 570 15 [134] 
airway 
epithelial 
brushing 
trizol extraction, 
15ug cRNA, 
16 hr, 45C, 
Fluidics 
Station 450 
RMA 
Qiagen RNeasy 
Kit 
Expression 
Analysis 
Technical Manual 
Z GSE8581 570 16 [30] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual 
20ug cRNA 
45C overnight, 
450 Fluidics 
Station 
MAS5.0 
           63               
Adeno-carcinoma 
(ADC) 
B GSE10072 96 58 [135] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical 
Manual  
RMA 
(Bioconductor) 
Qiagen RNeasy 
Kit,  
   Expression Analysis 
Technical Manual 
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Table 11 (cont.) 
Phenotype Study ID 
Study 
Label GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Original Pre-
processing 
Method 
Adeno-
carcinoma 
(ADC) 
C GSE10245 570 40 [136] 
resection, 
snap 
frozen 
tumor 
Qiagen RNeasy Kit 
Expression 
Analysis 
Technical 
Manual. 
GCRMA 
(Bioconductor) 
D GSE10445 570 59 [137] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual  
RMA 
   E GSE10799 570 16 [138] 
resection, 
snap 
frozen 
tumor 
Expression Analysis 
Technical Manual 
protocol 
50ng cRNA, 
16hr 45C, 
Fluidics 
Station 450 
stain, 
GeneChip 
Scanner 7G 
GCRMA 
   G GSE12667 570 75 [139] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5 
  
H GSE14814 96 28 [140] 
resection, 
snap 
frozen 
tumor 
guanidium 
isothiocyanate 
solution 
homogenization, 
Expression 
Analysis 
Technical 
Manual   
RMAexpress v0.3 
   acid phenol-chloroform extraction 
  
I E-TABM-15 96 23 
Blum 
resection, 
snap 
frozen 
tumor 
Superscript ds-cDNA 
synthesis kit,  Expression Analysis 
Technical 
Manual, 
Fluidics 
Station 
Protocol 
MAS5.0   no paper 
ENZO Bioarray hi 
yield RNA transcript 
labeling kit,  
     Qiagen RNeasy Kit purification 
  L GSE17475 96 28 [141] 
resection, 
snap 
frozen 
tumor 
Qiashredder, Qiagen 
RNeasy Kit  RNA 
extraction 
Expression 
Analysis 
Technical 
Manual. 
MAS5.0 
   M GSE18842 570 14 [142] 
resection, 
snap 
frozen 
tumor 
Expression Analysis 
Technical Manual  
protocol 
Expression 
Analysis 
Technical 
Manual  
protocol 
RMA 
  
O GSE19188 570 45 [143] 
resection, 
snap 
frozen 
tumor 
trizol extraction,  20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA    Qiagen RNeasy Kit, 
   Expression Analysis Technical Manual 
   P GSE2109 570 60 [144] 
resection, 
snap 
frozen 
tumor 
Expression Analysis 
Technical Manual 
protocol 
Expression 
Analysis 
Technical 
Manuall 
MAS5 
   Q E-MEXP-231 96 49 [145] 
resection, 
snap 
frozen 
tumor 
GeneChip Expression 
Analysis Technical 
Manual protocol 
GeneChip 
Expression 
Analysis 
Technical 
Manual 
protocol 
MAS5.0 
   R GSE3141 570 58 [146] 
resection, 
snap 
frozen 
tumor 
Expression Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
MAS5 
   X GSE7670 96 27 [147] 
resection, 
snap 
frozen 
tumor 
Expression Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
MAS5.0 
         580           
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Table 11 (cont.) 
Phenotype Study ID 
Study 
Label GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Original Pre-
processing 
Method 
Squamous Cell 
Carcinoma (SCC) C GSE10245 570 18 [136] 
resection, 
snap 
frozen 
tumor 
Qiagen RNeasy 
Kit purification Expression Analysis 
Technical 
Manual 
GCRMA 
Expression 
Analysis 
Technical Manual 
(Bioconductor) 
  
H GSE14814 96 52 [140] 
resection, 
snap 
frozen 
tumor 
guanidium 
isothiocyanate 
solution 
homogenization, 
Expression 
Analysis 
Technical 
Manual  
protocol 
RMAexpress v0.3 
   acid phenol-chloroform 
extraction 
  M GSE18842 570 32 [142] 
resection, 
snap 
frozen 
tumor 
Qiagen RNAeasy 
Mini Kit 
extraction 
Expression 
Analysis 
Technical Manual   
Expression 
Analysis 
Technical 
Manual   
RMA 
   O GSE19188 570 27 [143] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA 
   P GSE2109 570 39 [144] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5 
  
R GSE3141 570 53 [146] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual 
MAS5 
V GSE6253 96 18 [148] 
resection, 
snap 
frozen 
tumor 
flash frozen 
standard protocol, 
1-5ug RNA used 
Expression 
Analysis 
Technical 
Manual   
RMA 
           239               
Large Cell 
Carcinoma 
(LCLC) 
C GSE10445 570 13 [137] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
RMA 
  
H GSE14814 96 10 [140] 
resection, 
snap 
frozen 
tumor 
guanidium 
isothiocyanate 
solution 
homogenization, 
Expression 
Analysis 
Technical 
Manual   
RMAexpress v0.3 
  
acid phenol-
chloroform 
extraction 
O GSE19188 570 19 [143] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis 
Technical Manual  
20ug cRNA 
16hr 45C, 450 
Fluidics 
Station, 
GeneChip 
Scanner 3000 
RMA 
   P GSE2109 570 7 [144] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5 
           49               
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Table 11 (cont.) 
Phenotype Study ID 
Study 
Label GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Original Pre-
processing 
Method 
Normal 
(NORM) 
A GSE994 96 75 [149] 
airway 
epithelial 
brushing 
trizol extraction, 
Expression 
Analysis Technical 
Manual  
Expression 
Analysis 
Technical 
Manual   
MAS5.0 
B GSE10072 96 49 [135] 
resection, 
snap 
frozen 
tissue 
trizol extraction, 
Qiagen RNeasy Kit 
purification, 
Expression 
Analysis Technical 
Manual  
Expression 
Analysis 
Technical 
Manual 
RMA 
(Bioconductor) 
   E GSE10799 570 3 [138] 
resection, 
snap 
frozen 
tissue 
Expression 
Analysis Technical 
Manual protocol 
50ng cRNA, 
16hr 45C, 450 
Fluidics Station 
stain, GeneChip 
Scanner 7G 
GCRMA 
   F GSE12345 570 4 [150] 
resection, 
snap 
frozen 
tissue 
stored in 
RNAlater,Rneasy 
extraction 
15ug sample 
fragmented to 
20-200bp. 450 
Fluidics Station 
GCRMA 
  
I E-TABM-15 96 18 
Blum 
resection, 
snap 
frozen 
tumor 
Superscript ds-
cDNA synthesis 
kit, ENZO 
Bioarray hi yield 
RNA transcript 
labeling kit, Qiagen 
RNeasy Kit 
purification 
Expression 
Analysis 
Technical 
Manual, Fluidics 
Station Protocol 
MAS5.0 
   no paper 
J GSE1643 570 40 [151] 
resection, 
snap 
frozen 
tissue 
Qiagen MiniElute 
protocol extraction, 
Expression 
Analysis 
Technical 
Manual  protocol 
GCRMA 
  
ENZO Affymetrix  
cRNA synthesis 
K GSE1650 96 12 [131] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
8-10ug cRNA, 
overnight, 
Agilent confocal 
laser scanning 
RMA   
Superscript II 
reverse trans-
criptase, oligo dT 
primer, T7 RNA 
pol promoter, 
ENZO Bioarray 
transcript labeling, 
Qiagen RNeasy Kit 
purification 
  
M GSE18842 570 45 [142] 
resection, 
snap 
frozen 
tumor 
Qiagen RNAeasy 
Mini Kit extraction 
Expression 
Analysis 
Technical 
Manual   
RMA 
N GSE18965 96 7 [129] 
airway 
epithelial 
brushing 
Qiagen RNeasy Kit 
extraction 
15ug cRNA, 16 
hr, 45C, Fluidics 
Station 450 
GCRMA 
(Bioconductor) 
   O GSE19188 570 65 [143] 
resection, 
snap 
frozen 
tumor 
trizol extraction, 
Expression 
Analysis Technical 
Manual  
20ug cRNA 16hr 
45C, 450 
Fluidics Station, 
GeneChip 
Scanner 3000 
RMA 
  
Q E-MEXP-231 96 9 [145] 
resection, 
snap 
frozen 
tumor 
Expression 
Analysis Technical 
Manual, GNF 
Fluidics station 
cDNA synthesis 
GeneChip 
Expression 
Analysis 
Technical 
Manual protocol 
MAS5.0 
S GSE4302 570 44 [130] 
airway 
epithelial 
brushing 
NuGen Ovation 
RNA amplification 
2.75ug cRNA, 16 
hr, 45C, Fluidics 
Station 450 
RMA 
(Bioconductor) 
   T E-MTAB-47 570 12 [152] 
resection, 
snap 
frozen 
tumor 
Homogenized with 
MagnaLyser and 
70uL lysis buffer. 
Isolation with High 
Pure RNA Tissue 
Kit 
Quality Control 
with NanoDrop 
and Bioanalyzer 
RMA 
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Table 11 (cont.) 
Phenotype Study ID 
Study 
Label GPL Samples Citation 
Sample 
Type 
RNA Extraction 
Method 
Hybridization 
Protocol 
Original Pre-
processing 
Method 
Normal 
(NORM) U GSE5058 570 24 
[132, 
133] 
airway 
epithelial 
brushing 
trizol extraction, 
Qiagen RNeasy 
Kit purification,  15ug cRNA, 16 hr, 45C, Fluidics 
Station 450 
RMA 
Expression 
Analysis 
Technical Manual  
  
X GSE7670 96 27 [147] 
resection, 
snap 
frozen 
tissue 
Expression 
Analysis 
Technical Manual  
Expression 
Analysis 
Technical Manual   
MAS5.0 
Y GSE8545 570 16 [134] 
airway 
epithelial 
brushing 
trizol extraction, 
Qiagen RNeasy 
Kit purification,  15ug cRNA, 16 hr, 45C, Fluidics 
Station 450 
RMA 
   Expression Analysis 
Technical Manual  
   Z GSE8581 570 19 [30] 
resection, 
snap 
frozen 
tissue 
Expression 
Analysis 
Technical Manual  
20ug cRNA 45C 
overnight, 450 
Fluidics Station 
MAS5.0 
            469               
 
 
  93
APPENDIX B: Supplementary Information for Chapter 3 
Double metabolic gene deletions simulated by iSM-MTB-810 
To identify potential synthetic lethal gene deletion targets, we simulated double metabolic gene deletions 
with iSM-MTB-810. Figure 35 visualizes the predicted growth results from the double gene deletion 
simulations (the genes that result in single gene deletion lethality are not shown). The simulations found 
multiple synthetic lethal and synthetic sick gene pair deletions. 
 
Figure 35. Heatmap of growth ratios of double metabolic gene deletions relative to wild-type simulated using 
iSM-MTB-810. The rows and columns represent the The heatmap includes only metabolic genes that do not result 
in lethality in the single gene deletion case. A ratio of 1 (white) indicates that the overexpression results in wild-type 
growth, and a ratio of 0 (black) indicates that the overexpression results in no growth. 
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APPENDIX C: Supplementary Information for Chapter 4 
Condition-specific MTBPROM2.0 TFOE phenotype predictions 
To test for condition-specific TF perturbation phenotypes, we simulated TF overexpression and deletion 
phenotypes with MTBPROM2.0 while applying different carbon source, nitrogen source, and metabolite 
supplementation conditions. For each carbon and nitrogen source that the metabolic model iSM-MTB-
810 correctly predicted growth (Table 4 and Table 6), we simulated TF perturbation growth phenotypes 
with and without the presence of supplementation metabolites listed in Table 12. The results are 
visualized as heatmaps in Figure 36 and Figure 37. 
 
Figure 36. Heatmap of growth ratios of TFOE perturbations relative to uninduced TF under a broad range of 
simulated media conditions. The rows represent each TF overexpression perturbation, and the columns represent 
each simulated media condition. The media conditions consist of the different carbon and nitrogen sources that iSM-
MTB-810 can successfully grow on, paired with individual supplementation of each metabolite that has an exchange 
reaction in the model. The predictions show condition-specific growth defects resulting from TF overexpression. A 
ratio of 1 (white) indicates that the overexpression results in wild-type growth, and a ratio of 0 (black) indicates that 
the overexpression results in no growth. 
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Figure 37. Heatmap of growth ratios of TF knockout perturbations relative to wildtype under a broad range 
of simulated media conditions. The rows represent each TF overexpression perturbation, and the columns 
represent each simulated media condition. The media conditions consist of the different carbon and nitrogen sources 
that iSM-MTB-810 can successfully grow on, paired with individual supplementation of each metabolite that has an 
exchange reaction in the model. The predictions show condition-specific growth defects resulting from TF 
overexpression. A ratio of 1 (white) indicates that the overexpression results in wild-type growth, and a ratio of 0 
(black) indicates that the overexpression results in no growth. 
 
TF-metabolic double gene deletions simulated by iSM-MTB-810 
To search for potential synergistic effects of double gene deletions involving transcription factors, we 
simulated the growth phenotype of TF-metabolic double gene deletions with MTBPROM2.0. To 
accomplish this, we generated a metabolic model representing the metabolic state of each metabolic gene 
deletion (i.e. each gene deletion model had the reactions associated with the deleted gene blocked). We 
used the PROM framework using these gene deletion models as the metabolic component and calculated 
the resulting predicted growth rate relative to wild-type. Figure 38 visualizes the growth ratios relative to 
wild-type generated from the double deletion simulationes (we included only the metabolic genes that did 
not cause a single gene deletion lethal phenotype). Table 13 lists the top synthetic sick gene pair 
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candidates determined from these analyses. For each of the synthetic sick TF-metabolic gene pairs, the 
double knockout was predicted to have a markedly greater growth defect than achieved by either of the 
single gene deletions. 
 
Figure 38. Heatmap of growth ratios of TF-metabolic gene double knockout perturbations relative to 
wildtype. The rows represent each metabolic gene knockout, and the columns represent each TF knockout. The 
heatmap includes only metabolic genes that do not result in lethality in the single gene deletion case. A ratio of 1 
(white) indicates that the overexpression results in wild-type growth, and a ratio of 0 (black) indicates that the 
overexpression results in no growth. 
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Table 12. Metabolite supplementation conditions tested. These are the exchange reactions that were used to test 
metabolite supplementation conditions. For each metabolite, the corresponding reaction flux is turned on to simulate 
its presence in the environmental condition. These adjustments were used with MTBPROM2.0 to simulate the results 
shown in Figure 36 and Figure 37. 
Reaction 
ID Reaction Name Reaction Formula 
R800 ammonia transport via diffusion  <=> NH3  
R801 nitrate transport H  <=> NO3  
R803 passive diffucion of nitrite out of the cell  <=> NO2  
R804 oxygen transport via diffusion  <=> O2  
R805 CO2 transport via diffusion  <=> CO2  
R806 formate transport via diffusion  -> FOR  
R807 glycolate transport via diffusion  -> GLYCOLATE  
R808 acetate transport via diffusion  -> AC  
R809 acetaldehyde transport via facilitated diffusion  -> ACAL  
R810 anthranilate transport via facilitated diffusion  -> AN  
R811 citrulline transport via facilitated diffusion  -> CITR  
R812 
glycerol transport via channel/putative glycerol 
uptake facilitator protein   -> GL  
R814 guanine transport via facilitated diffusion  -> GN  
R815 hypoxanthine transport via facilitated diffusion  -> HYXN  
R816 nicotinic acid transport via facilitated diffusion  -> NAC  
R817 glyceraldehyde transport via facilitated diffusion  -> T3  
R818 urea transport via facilitated diffusion  -> UREA  
R819 xanthine transport via facilitated diffusion  -> XAN  
R820 L-alanine transport via ABC system ATP  -> ADP + ALA  
R821 L-arginine transport via ABC system ATP  -> ADP + PI + ARG  
R822 
L-asparagine transport via ABC system/ 
putative L-asparagine permease  ATP  -> ADP + PI + ASN  
R823 L-aspartate transport via ABC system ATP  -> ADP + PI + ASP  
R824 
Sucrose transport via ABC system/ 
putative cellobiose transport permease  ATP  -> ADP + PI + SUC  
R825 
cellobiose transport via ABC system/ 
putative cellobiose transport permease  ATP  -> ADP + PI + CELB  
R826 L-cysteine transport via ABC system ATP  -> ADP + PI + CYS  
R827 2,6-diaminopimelic acid transport via ABC system ATP  -> ADP + PI + DAPIM  
R828 D-glutamate transport via ABC system ATP  -> ADP + PI + DGLU  
R829 
L-glutamine binding (glnH) and transport via ABC 
system (glnQ) ATP  -> ADP + PI + GLN  
R830 glutamate transport via ABC system ATP  -> ADP + PI + GLU  
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Table 12 (cont.) 
Reaction 
ID Reaction Name Reaction Formula 
R831 L-histidine transport via ABC system ATP  -> ADP + PI + HIS  
R832 L-isoleucine transport via ABC system ATP  -> ADP + PI + ILE  
R833 L-leucine transport via ABC system ATP  -> ADP + PI + LEU  
R834 L-lysine transport via ABC system ATP  -> ADP + PI + LYS  
R835 L-methionine transport via ABC system ATP  -> ADP + PI + MET  
R836 maltose transport via ABC system ATP  -> ADP + PI + MLT  
R837 ornithine transport via ABC system 
ATP + ORNxt  -> ADP + PI + 
ORN  
R838 phosphate transport via ATPase ATP  -> ADP + 2 PI  
R839 L-proline transport via ATPase ATP  -> ADP + PI + PRO  
R840 D-ribose transport via ABC system ATP  -> ADP + RIB + PI  
R841 
sulfate transport via ABC system cysTWA and 
sulfate-binding lipoprotein, subI ATP  -> ADP + PI + SLF  
R842 L-threonine transport via ABC system ATP  -> ADP + PI + THR  
R843 L-valine transport via ABC system ATP  -> ADP + PI + VAL  
R844 acetate transport via proton symport H  -> AC  
R845 adenine transport via proton symport H  -> AD  
R846 adenosine transport via proton symport H  -> ADN  
R847 2-oxoglutarate transport via proton symport H  -> AKG  
R848 L-aspartate transport in via proton symport H  -> ASP  
R849 L-aspartate transport via proton symport (2 H) 2 H  -> ASP  
R850 L-asparate transport via proton symport (3 H) 3 H  -> ASP  
R851 citrate transport via protone symport 3 H  -> CIT  
R852 deoxyadenosine transport via proton symport H  -> DA  
R853 D-alanine transport via proton symport H  -> DALA  
R854 deoxycytidine transport via proton symport H  -> DC  
R855 deoxyinosine transport via proton symport H  -> DIN  
R856 thymidine transport via proton symport H  -> DT  
R857 deoxyuridine transport via proton symport H  -> DU  
R858 ethanol transport via proton symport H  -> ETH  
R859 fumarate transport via proton symport (2 H) 2 H  -> FUM  
R860 fumarate transport via proton symport (3 H) 3 H  -> FUM  
R861 4-aminobutyrate transport via proton symport H  -> GABA  
R862 D-galactose transport in via proton symport H  -> GLAC  
R863 D-glucose uptake via proton symport H  -> GLC  
R864 L-glutamate efflux via proton symport H  -> GLU  
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Table 12 (cont.) 
Reaction 
ID Reaction Name Reaction Formula 
R865 
D-gluconate transport via proton symport/putative 
gluconate permease H  -> GLUC  
R866 glycine transport via proton symport H  -> GLY  
R867 guanosine transport via proton symport H  -> GSN  
R868 L-histidine transport via proton symport H  -> HIS  
R869 L-histidine transport via proton symport HIS  -> H  
R870 L-isoleucine transport via proton symport H  -> ILE  
R871 L-isoleucine transport via proton symport ILE  -> H  
R872 inosine transport via proton symport H  -> INS  
R873 D-lactate transport via proton symport H  -> LAC  
R874 L-leucine transport via proton symport H  -> LEU  
R875 L-leucine transport via proton symport LEU  -> H  
R876 
L-lactate transport via proton symport/putative L-
lactate permease  H  -> LLAC  
R877 L-lysine reversible transport via proton symport H  -> LYS  
R878 L-lysine reversible transport via proton symport LYS  -> H  
R879 malate transport via proton symport (2 H) 2 H  -> MAL  
R880 malate transport via proton symport (3 H) 3 H  -> MAL  
R881 L-phenylalanine transport via proton symport H  -> PHE  
R882 
phosphate reversible transport via symport/ phosphate 
transport protein  H  -> PI  
R883 L-proline transport via proton symport H  -> PRO  
R884 L-proline transport via proton symport PRO  -> H  
R885 pyruvate transport via proton symport H  -> PYR  
R886 L-serine transport via proton symport H  -> SER  
R887 L-serine transport via proton symport SER  -> H  
R888 succinate transport via proton symport (2 H) 2 H  -> SUCC  
R889 succinate transport via proton symport (3 H) 3 H  -> SUCC  
R890 succinate efflux via proton symport SUCC  -> H  
R891 L-threonine transport via proton symport H  -> THR  
R892 L-threonine transport via proton symport THR  -> H  
R893 L-tryptophan transport via proton symport H  -> TRP  
R894 L-tyrosine transport via proton symport H  -> TYR  
R895 uracil transport via proton symport H  -> URA  
R896 uridine transport via proton symport H  -> URI  
R897 L-valine transport via proton symport H  -> VAL  
R898 L-valine transport via proton symport VAL  -> H  
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Table 12 (cont.) 
Reaction 
ID Reaction Name Reaction Formula 
R899 fructose transport via PEP:PTS PEP  -> F6P + PYR  
R900 fructose transport via PEP:PTS PEP  -> F1P + PYR  
R901 D-mannose transport via PEP:PTS PEP  -> MAN6P + PYR  
R902 trehalose transport via PEP:PTS PEP  -> TRE6P + PYR  
R903 lysine/cadaverine antiporter H + CADA  -> LYS  
R904 citrate transport via succinate antiport SUCC  -> CIT  
R905 succinate/fumarate antiporter SUCC  -> FUM  
R906 glycerol-3-phosphate/phosphate antiporter PI  -> GL3P  
R907 fatty acid transport protein (FATP)  -> PROPANOATE  
R908 fatty acid transport protein (FATP)  -> HEXANOATE  
R909 fatty acid transport protein (FATP)  -> HEXACOSANOATE  
R910 fatty acid transport protein (FATP)  -> TETRACOSANOATE  
R911 fatty acid transport protein (FATP)  -> TETRADECANOATE  
R912 fatty acid transport protein (FATP)  -> EICOSANOATE  
R913 fatty acid transport protein (FATP)  -> PENTADECANOATE  
R914 fatty acid transport protein (FATP)  -> HEPTADECANOATE  
R915 fatty acid transport protein (FATP)  -> NONADECANOATE  
R916 fatty acid transport protein (FATP)  -> HEXADECANOATE  
R917 fatty acid transport protein (FATP)  -> 9_HEXADECENOATE  
R918 fatty acid transport protein (FATP)  -> 9_OCTADECENOATE  
R919 fatty acid transport protein (FATP)  -> PENTADECANOATE  
R920 fatty acid transport protein (FATP)  -> DODECANOATE  
R921 TAG transporter  -> TAGcat  
R922 host lipid transport  -> PHOSPHATIDYLCHOLINE 
R923 mycobactin-mediated iron uptake 
ATP + 0.001 MBTSEC + 0.001 
MBTWALL  -> ADP + PI + FE3 
R924 iron uptake via citrate  -> CIT + FE3  
R925 biotin transport  -> BIOTIN  
R926 Cobalt transport  -> CO_II  
R927 Molybdenum transport  -> MO2  
R928 secreted protease BSA  ->  
R929 Electrophile-x transport  -> ELECTROPHILE[X]  
R930 H2X transport  -> H2X  
R931 N acetyl S conjugate 
 -> 
N_ACETYL_S_CONJUGATE  
R932 
cholesterol uptake (mce4 locus and supAB and 
mceG) 
CHOLESTEROLxt  -> 
CHOLESTEROL  
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Table 13. Top synthetic sick gene pair predictions from TF-metabolic gene double gene deletion simulations. 
For each of these genes, the double knockout is predicted to have a substantially lower growth rate relative to wild-
type than achieved by deleting either gene individually. 
Met Gen TF 
Double 
Deletion 
Ratio 
Metabolic 
Gene 
Deletion 
Ratio 
TF 
Deletion 
Ratio 
Rv1098c Rv1186c 0.36 0.94 1.00 
Rv1811 Rv2642 0.68 1.00 1.00 
Rv1448c Rv1219c 0.56 0.90 0.80 
Rv3145 Rv2250c 0.38 0.65 0.58 
Rv3145 Rv3223c 0.38 0.65 0.58 
Rv3145 Rv0054 0.37 0.65 0.57 
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Table 14. Parameters tested for association with the likelihood that the MTBPROM2.0 would correctly 
predict the overexpression growth phenotype of each TF. 
TF 
PROM 
correct 
prediction 
# 
Metabolic 
Targets 
# 
Essential 
Metabolic 
Targets 
Fraction 
Essential 
Targets 
Average 
# TFs 
for 
Essential 
Targets 
# 
Combinatorial 
TFs for 
Essential 
Targets 
PROM 
growth 
STD 
iMAT 
agree 
PROM 
Rv0022c FALSE 5 3 0.6 1.67 2 3.61E-03 TRUE 
Rv0023 TRUE 12 4 0.33 3.75 4 9.64E-04 TRUE 
Rv0042c TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv0047c FALSE 31 10 0.32 4.2 6 2.07E-20 FALSE 
Rv0054 FALSE 1 1 1 4 1 1.29E-02 FALSE 
Rv0081 TRUE 90 26 0.29 4.23 23 3.57E-04 FALSE 
Rv0135c FALSE 13 7 0.54 2 4 3.90E-03 FALSE 
Rv0158 TRUE 1 1 1 5 1 2.22E-16 TRUE 
Rv0195 TRUE 1 0 0 0 0 2.22E-16 FALSE 
Rv0212c TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv0238 TRUE 1 0 0 0 0 3.39E-03 TRUE 
Rv0273c TRUE 2 0 0 0 0 2.22E-16 TRUE 
Rv0275c TRUE 0 0 0 0 0 7.99E-17 TRUE 
Rv0302 FALSE 19 12 0.63 3.17 6 1.50E-03 FALSE 
Rv0324 TRUE 21 10 0.48 3.2 8 7.56E-04 TRUE 
Rv0330c TRUE 0 0 0 0 0 2.22E-16 FALSE 
Rv0339c TRUE 1 1 1 1 0 6.67E-13 FALSE 
Rv0353 TRUE 2 0 0 0 0 2.22E-16 TRUE 
Rv0465c FALSE 14 5 0.36 5.6 5 4.45E-04 FALSE 
Rv0472c TRUE 2 2 1 3.5 2 2.22E-16 TRUE 
Rv0494 FALSE 18 10 0.56 2.5 6 1.24E-03 FALSE 
Rv0576 TRUE 1 0 0 0 0 2.22E-16 FALSE 
Rv0602c FALSE 7 2 0.29 5 1 9.20E-05 FALSE 
Rv0653c TRUE 2 0 0 0 0 2.22E-16 TRUE 
Rv0674 TRUE 3 0 0 0 0 2.22E-16 TRUE 
Rv0678 TRUE 60 27 0.45 3.52 21 2.80E-04 FALSE 
Rv0681 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv0691c FALSE 20 5 0.25 3.2 3 7.58E-03 FALSE 
Rv0735 TRUE 2 0 0 0 0 2.22E-16 TRUE 
Rv0757 TRUE 1 0 0 0 0 3.75E-03 TRUE 
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Table 14 (cont.) 
TF 
PROM 
correct 
prediction 
# 
Metabolic 
Targets 
# 
Essential 
Metabolic 
Targets 
Fraction 
Essential 
Targets 
Average 
# TFs 
for 
Essential 
Targets 
# 
Combinatorial 
TFs for 
Essential 
Targets 
PROM 
growth 
STD 
iMAT 
agree 
PROM 
Rv0767c FALSE 42 15 0.36 3.13 8 1.90E-04 FALSE 
Rv0818 FALSE 0 0 0 0 0 2.22E-16 FALSE 
Rv0880 TRUE 8 2 0.25 4.5 2 6.22E-13 TRUE 
Rv0967 FALSE 78 38 0.49 2.34 19 6.13E-04 FALSE 
Rv0981 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1019 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1033c FALSE 59 25 0.42 3.4 18 3.02E-04 FALSE 
Rv1049 TRUE 51 23 0.45 3.57 19 4.82E-14 FALSE 
Rv1167c TRUE 1 1 1 4 1 2.22E-16 TRUE 
Rv1186c TRUE 1 1 1 1 0 2.22E-16 FALSE 
Rv1189 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1219c FALSE 0 0 0 0 0 2.22E-16 FALSE 
Rv1255c TRUE 4 3 0.75 1.67 2 7.31E-13 TRUE 
Rv1287 FALSE 2 2 1 2 2 1.73E-04 TRUE 
Rv1332 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1353c FALSE 43 19 0.44 2.84 12 1.27E-03 FALSE 
Rv1395 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1404 FALSE 3 1 0.33 4 1 2.13E-03 FALSE 
Rv1423 TRUE 1 0 0 0 0 1.27E-02 TRUE 
Rv1460 TRUE 1 1 1 3 1 2.22E-16 TRUE 
Rv1473A TRUE 0 0 0 0 0 6.99E-03 FALSE 
Rv1556 FALSE 2 2 1 2 2 5.77E-03 FALSE 
Rv1657 FALSE 6 4 0.67 5 4 2.95E-04 FALSE 
Rv1674c TRUE 1 0 0 0 0 1.06E-12 TRUE 
Rv1719 FALSE 11 7 0.64 3 3 2.82E-03 FALSE 
Rv1776c TRUE 1 1 1 3 1 9.41E-07 FALSE 
Rv1816 FALSE 63 32 0.51 3.34 27 6.15E-04 FALSE 
Rv1828 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1846c TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv1956 FALSE 14 7 0.5 3.57 7 3.46E-03 FALSE 
Rv1985c FALSE 17 2 0.12 3.5 1 3.52E-03 FALSE 
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Table 14 (cont.) 
TF 
PROM 
correct 
prediction 
# 
Metabolic 
Targets 
# 
Essential 
Metabolic 
Targets 
Fraction 
Essential 
Targets 
Average 
# TFs 
for 
Essential 
Targets 
# 
Combinatorial 
TFs for 
Essential 
Targets 
PROM 
growth 
STD 
iMAT 
agree 
PROM 
Rv1990c FALSE 11 7 0.64 3.86 5 3.23E-04 FALSE 
Rv1994c TRUE 4 2 0.5 2.5 1 5.95E-03 TRUE 
Rv2009 TRUE 3 1 0.33 6 1 1.64E-07 TRUE 
Rv2011c FALSE 28 13 0.46 5.31 13 2.89E-04 FALSE 
Rv2021c TRUE 0 0 0 0 0 2.22E-16 FALSE 
Rv2034 TRUE 31 11 0.35 4.27 8 3.33E-04 TRUE 
Rv2069 TRUE 1 0 0 0 0 2.22E-16 FALSE 
Rv2250c TRUE 38 13 0.34 3.23 10 2.08E-04 FALSE 
Rv2324 FALSE 30 13 0.43 3.77 11 3.74E-04 TRUE 
Rv2374c TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv2506 TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv2642 TRUE 3 1 0.33 6 1 1.44E-07 FALSE 
Rv2745c TRUE 0 0 0 0 0 2.22E-16 TRUE 
Rv2779c FALSE 1 0 0 0 0 4.50E-04 FALSE 
Rv2827c TRUE 1 1 1 5 1 4.41E-13 TRUE 
Rv2887 FALSE 6 6 1 4.17 6 1.20E-03 TRUE 
Rv2989 FALSE 19 12 0.63 2 7 1.59E-04 FALSE 
Rv3050c TRUE 1 0 0 0 0 2.22E-16 TRUE 
Rv3066 TRUE 3 1 0.33 2 1 5.45E-13 TRUE 
Rv3082c TRUE 4 0 0 0 0 2.22E-16 TRUE 
Rv3133c FALSE 43 12 0.28 4.25 11 3.00E-04 TRUE 
Rv3167c FALSE 1 1 1 2 1 1.21E-05 FALSE 
Rv3173c TRUE 1 0 0 0 0 7.23E-04 TRUE 
Rv3219 TRUE 2 2 1 3 2 6.12E-13 TRUE 
Rv3246c TRUE 1 1 1 5 1 2.15E-16 TRUE 
Rv3249c FALSE 15 10 0.67 4.5 10 3.96E-03 FALSE 
Rv3260c TRUE 0 0 0 0 0 2.22E-16 FALSE 
Rv3286c TRUE 1 0 0 0 0 2.22E-16 FALSE 
Rv3291c FALSE 3 1 0.33 9 1 1.11E-02 FALSE 
Rv3405c TRUE 1 1 1 5 1 2.22E-16 TRUE 
Rv3416 FALSE 1 0 0 0 0 2.22E-16 FALSE 
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Table 14 (cont.) 
TF 
PROM 
correct 
prediction 
# 
Metabolic 
Targets 
# 
Essential 
Metabolic 
Targets 
Fraction 
Essential 
Targets 
Average 
# TFs 
for 
Essential 
Targets 
# 
Combinatorial 
TFs for 
Essential 
Targets 
PROM 
growth 
STD 
iMAT 
agree 
PROM 
Rv3488 FALSE 6 4 0.67 3.25 3 3.28E-04 FALSE 
Rv3557c FALSE 8 2 0.25 7.5 2 1.10E-06 FALSE 
Rv3574 FALSE 19 8 0.42 3.25 8 5.39E-03 TRUE 
Rv3597c FALSE 29 9 0.31 5.67 9 2.68E-03 FALSE 
Rv3676 FALSE 0 0 0 0 0 2.22E-16 TRUE 
Rv3681c TRUE 2 0 0 0 0 8.76E-13 TRUE 
Rv3736 FALSE 12 4 0.33 1.75 3 8.03E-05 FALSE 
Rv3765c FALSE 3 2 0.67 2 1 1.15E-03 TRUE 
Rv3830c FALSE 24 15 0.63 3 14 3.11E-05 FALSE 
Rv3849 FALSE 1 0 0 0 0 8.55E-04 FALSE 
Rv3855 FALSE 3 2 0.67 7.5 2 3.29E-06 FALSE 
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